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Diabetes mellitus is a metabolic disorder marked by chronic hyperglycaemia. 
Around 90% of the cases are diagnosed as type 2 diabetes. Insulin resistance and 
impaired insulin secretion are the two main features of the disorder. Complications of 
diabetes impose major public health burdens worldwide, for example, about 15% of 
the patients develop foot ulcer. In a clinical study, two traditional Chinese medicine 
formulae,托毒生肌顆粒劑（formula 1) and耆味地黃顆粒劑（formula 2)，have 
saved over 80% of the diabetic foot ulcer patients from amputation. We would like 
to explode the possibilities that the formulae and their individual components may 
possess anti-diabetic activities since glycaemic control of the foot ulcer patients is 
one of the effective ways to treat the ulcer. The studies in this project test the 
hypothesis that formula 1 and its six component herbs have anti-diabetic activities. 
The six component herbs of formula 1 were firstly authenticated by their 
morphological characteristics, and further supported by thin layer chromatographic 
profiles. The herbal extracts were then screened for their effects on: (1) Glucose 
uptake in 3T3-L1 adipocytes and Hs68 skin fibroblasts; (2) Gluconeogenesis in 
H4IIE hepatoma cells; (3) Glucose absorption in brush border membrane vesicles. 
The screening results indicated that formula 1 and its component herb, Rhizoma 
Smilacis Chinensis ( g 葜)，are highly potent on regulating cellular glucose 
homeostasis. These two herbal extracts were further tested for their in vivo anti-
diabetic activities using a streptozotocin(STZ)~mduced type 2 diabetic rat model. The 
results showed that formula 1 and Rhizoma Smilacis Chinensis did not significantly 
improve the oral glucose tolerance and basal glycaemia in the diabetic rats. The 
effects of formula 1 and formula 2 on glucose homeostasis were also studied in 
i 
diabetic patients. Preliminary results showed that the formulae did not significantly 
improve fasting plasma glucose level or erythrocyte glucose transport. In conclusion, 
a systematic approach has been developed and used to investigate the anti-diabetic 
activities of traditional Chinese medicine. The results indicate that formula 1 and its 
component herbs modulate glucose homeostasis at the tissue levels without 
improving systemic glycaemic control. From our results, we can tell that it is safe for 
the patients to receive both formulae and medication treatment without worrying 
about the side effect of hypoglycaemia. 
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Chapter 1: Introduction 
1.1. Definition of diabetes mellitus 
Diabetes is a major health burden in the world. According to the World Health 
Organization (WHO), it is estimated that there were about 171 million diabetes cases 
worldwide in 2000 and the number of cases is estimated to increase to 366 million by 
year 2030 (Wild et al., 2004). In Hong Kong, diabetes mellitus is also a prevalent 
disorder. About 10% of the population is suffering from diabetes (Diabetes Division, 
Hong Kong Society for Endocrinology, Metabolism, and Reproduction, 2000), and the 
number is still increasing. 
Diabetes mellitus is a metabolic disorder, which is characterized by the presence of 
chronic hyperglycaemia，and it is caused by insufficient insulin production from the 
pancreatic B-cells and/or ineffectiveness of insulin action of the target tissues (World 
Health Organization, 1999). 
The diagnosis criteria of diabetes were revised by American Diabetes Association 
in 2002 (American Diabetes Association., 2004)，which are shown in Table 1.1. The 
diagnosis is based on the measure of hyperglycaemia. Three criteria are considered, 
including casual plasma glucose level, fasting plasma glucose and 2-hour post glucose 
load plasma glucose during oral glucose tolerance test. The new diagnostic criteria state 
that any individual who fits the first criterion with diabetic symptoms or the second and 
third criteria being asymptotic is considered as a diabetic patient. Symptoms of diabetes 
include polyuria (excessive passage of urine), polydipsia (excessive thirst), weight loss, 
sometimes with polyphagia (excessive desire to eat), and ketoacidosis (acidosis with an 
accumulation of ketone bodies). , 
1 
Despite the use of a single factor of diagnosing diabetes, which is the measurement 
of hyperglycaemia, the aetiology and clinical presentations of diagnosed diabetic 
patients may be different. These differences among patients gave rise to the 
classification of diabetes, which is described in section 1.2. 
2 
Oral glucose 
Casual plasma Fasting plasma tolerance test 
glucose glucose 
(2hr post glucose load) 
Normal SlOOmg/dl <140 mg/dl 灿 rmal … (<5.5mM) (<7.7mM) 
Impaired 100-125 mg/dl 140-199 mg/dl 
glucose tolerance "“ (5.6 — 6.9mM) (7.7 — l l . l m M ) 
Diabetes >200 mg/dl >126 mg/dl >200 mg/dl 
(>ll.lmM) (>7.0mM) (> l l . lmM) 
Table 1,1. Diagnostic values of diabetes mellitus and other categories of 
hyperglycaemia, according to criteria published by American Diabetes Association. 
Casual plasma glucose is defined as the plasma glucose level at any time of day. Fasting 
is defined as no caloric intake for at least 8 hours. Oral glucose tolerance test should be 
performed by using a glucose load containing the equivalent of 75g glucose dissolved in 
water (American Diabetes Association，2004). 
3 
1.2. Classification of diabetes mellitus 
Diabetes mellitus was previously classified into insulin-dependent diabetes 
mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM). However，this 
classification did not consider the specific cause or aetiology of the disorder. In 1999， 
the classification of diabetes was revised by WHO and the new classification reflects the 
stages of hyperglycaemia, as well as the aetiology. Diabetes mellitus is now classified 
into mainly two types: type 1 and type 2 diabetes, which are different in aetiology, 
pathophysiology and clinical manifestation. Apart from the usual type 1 and type 2 
diabetes, there are also some less frequently occurring types of diabetes, including 
gestational diabetes, maturity-onset diabetes of the young (MODY) and diabetes 
secondary to other diseases (World Health Organization, 1999). 
1.2.1. Type 1 diabetes 
Type 1 diabetes, formerly known as IDDM or juvenile-onset diabetes, is 
caused by the pancreatic p-cells destruction and the failure of the pancreas to 
produce insulin. Patients with type 1 diabetes are prone to ketoacidosis and rely on 
insulin injection for survival. This form of diabetes develops most frequently in 
children and adolescents. Type 1 diabetes is regarded as an autoimmune disease that 
causes the destruction of B-cells of the Islet of Langerhans of pancreas (Mathis et al, 
2001) by activated lymphocytic T cells (Conget，2002)，resulting in insufficient 
insulin secretion and hyperglycaemia. Type 1 diabetes is characterized by the 
presence of autoantibodies to insulin, islet cells or glutamic acid decarboxylase 
(Winter et al., 2002). It is found that genetic factors may contribute to the 
susceptibility of individuals to the disorder, for example, the presence of certain 
halotypes in HLA genes on chromosome 6 (Conget, 2002). Epidemiological studies 
4 
also suggest that the disorder is related to environmental factors, which are still 
poorly defined (Zimmet et aL, 2001). However, few cases of type 1 diabetes, which 
are prone to ketoacidosis and require insulin for survival, do not exhibit autoimmune 
destruction of the pancreas. These patients are called "Type 1 idiopathic diabetes". 
These cases have no known aetiologies and they are strongly inherited, but with no 
evidence of autoimmune destruction (Tiberti et aL, 2000). 
1.2.2. Type 2 diabetes 
Type 2 diabetes, formerly known as NIDDM or maturity-onset diabetes, 
results from the body's inability to respond properly to the action of insulin produced 
by the pancreas and the inability of the p-cells to secrete enough insulin to overcome 
the inadequate response. It occurs most frequently in adults and it is the most 
prevalent form of diabetes, which accounts for around 90% of all diabetes cases 
worldwide (Williamson et aL, 2004). This type of diabetes is closely associated with 
affluent lifestyle and overweight. Patients with type 2 diabetes are characterized by 
the presence of insulin resistance and impaired insulin secretion. Insulin resistance is 
the reduced sensitivity of the insulin target tissues to the normal circulating level of 
insulin. It results in the decreased glucose disposal in muscle and adipose tissue and 
the lack of suppression on hepatic glucose output upon insulin action (Goldstein, 
2003), which in turn create a tendency to increase the blood glucose level. To 
maintain normoglycaemia, an increased amount of insulin is released by the 
pancreatic P-cells, resulting in hyperinsulinaemia. The co-occurrence of insulin 
resistance and hyperinsulinaemia characterizes the impaired glucose tolerance state, 
which precedes type 2 diabetes (Pirola et aL, 2003). However, sustained 
hyperinsulinaemia would cause impairment in insulin secretion and action 
5 
(Ostenson, 2001)，and result in pancreatic B-cell defects and impaired insulin 
secretion. The decrease in insulin secretion under the state of insulin resistance 
means that the plasma insulin level can no longer sustain normal glucose level and it 




^ ^ ^ Insulin resistance ^ Hyperinsulinaemia 
^ \ \ Z 
Environmental factors ^ ^ 
Compensated insulin resistance 
小 V 
Impaired glucose tolerance 
V 
Impaired insulin secretion 
Y 
Figure 1.1. The natural history of type 2 diabetes mellitus. Insulin resistance is 
predisposed by genetic and environmental factors. To maintain normoglycaemia in 
insulin resistant state, hyperinsulinaemia is needed. Sustained hyperinsulinaemia results 
in insulin secretion and action impairment and hence, pancreatic B-cells defects and 
impaired insulin secretion. Impaired insulin secretion, together with insulin resistance, 
cause hyperglycaemia and therefore, type 2 diabetes (Ostenson, 2001). 
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Type 2 diabetes is closely related to both genetic and environmental factors 
(Figure 1.1). Although diabetes caused by mutation of a single gene is identified， 
such as MODY，type 2 diabetes seems to be a polygenic disorder, rather than 
monogenic (Froguel and Velho, 2001). However, the genes involved in the 
pathogenesis of this disorder remain unidentified. Epidemiological studies found that 
the prevalence of type 2 diabetes is very high in certain ethnic groups，such as the 
American Pima Indians, Australian Aborigines and Pacific Islanders (Zimmet et al., 
2001). Studies among identical twins with type 2 diabetes show that the concordance 
rate can be as high as 90% (Lo et al,, 1991; Medici et al” 1999). These evidences 
suggest that diabetic phenotype is affected by genetic factors of the individuals. It is 
also generally known that type 2 diabetes segregates in families in an inherited 
condition. An offspring with one of the parents having type 2 diabetes has 3.5-fold 
greater risk to get the disorder when compared with another offspring without 
parental diabetes, while those with both parents having this disorder has a 6-fold 
higher risk (Meigs et al, 2000). 
Most cases of type 2 diabetes are strongly associated with sedentary 
lifestyle and obesity (Zimmet, 1999). Over 90% of the newly diagnosed patients 
are obese. Body mass index (BMI) is a strong predictor for type 2 diabetes. 
Research showed that the relative risk of developing diabetes increased linearly 
with BMI. A BMI of 23-25 can increase the risk of diabetes by 3-fold compared 
with a BMI of less than 21 (Carey et al, 1997). Individuals with BMI higher than 
35 have a 30-40-fold increased risk of diabetes (Adler, 2002). Obesity is a major 
factor of insulin resistance (Kahn and Flier, 2000). Insulin resistance occurs early 
in the development of obesity, long before any occurrence of diabetes. It is found 
8 
that insulin secretion is elevated in the course of an oral glucose tolerance test in 
obese subjects and the rise of insulin represents a compensatory mechanism for 
maintaining normoglycaemia. Insulin resistance is demonstrated by the reduction 
of non-oxidative glucose disposal (Felber and Golay，2002). Elevated plasma free 
fatty acids (FFA) level is also a major factor contributing insulin resistance in 
obesity. Plasma FFA induces insulin resistance through inhibition of cellular 
glucose disposal (Dresner et al., 1999). 
With the change of the lifestyle in most developed and developing 
countries, over-nutrition and sedentary lifestyle become more common. More type 
2 diabetes cases are expected and it will continue to impose an increasing burden 
on the healthcare system in the future. 
1.2.3. Other forms of diabetes 
Apart from type 1 and type 2 diabetes, there are several less common forms 
of diabetes. Table 1.2 summarizes these forms of diabetes. The causes of these forms 
of diabetes are in a large variation, from genetic defects to induction by drugs or 
infections. However, these cases constitute only a small proportion of the whole 
diabetes population (Expert Committee on the Diagnosis and Classification of 
Diabetes Mellitus, 2003). 
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Aetiology Types Examples 
Mitochondrial DNA mutation 
Genetic defects of P-cell function Chromosome 20, HNF-4a (MODYl) 
Chromosome 7，glucokinase (M0DY2) 
Type A insulin resistance 
Genetic defects in insulin action 
Leprechaunism 
Pancreatitis 
Diseases of the exocrine pancreas Cystic fibrosis 
Trauma/pancreatectomy 
Acromegaly 
Endocrinopathies Gushing's syndrome 
Glucagonoma 
Vacor 
Drug- or chemical-induced Thyroid hormone 
Infections Congenital rubella 
Uncommon forms of immune-mediated Anti-insulin receptor antibodies 
diabetes 
Down's syndrome 
Other genetic syndromes sometimes Klinefelter's syndrome 
associated with diabetes 
Turner's syndrome 
Gestational diabetes mellitus 
Table 1.2. The summary of other forms of diabetes mellitus. (Expert Committee on 
the Diagnosis and Classification of Diabetes Mellitus, 2003). 
10 
1.3. Complications of diabetes mellitus 
Cardiovascular complications, retinopathy, nephropathy, neuropathy and foot ulcer 
are the most common complications of diabetes. 
Cardiovascular complications’ such as coronary heart disease and strokes, are 
the most common cause of morbidity and mortality in diabetes. Hyperglycaemia 
promotes the formation of advanced glycation products，which cross-link with collagen, 
causing arterial stiffness. Dyslipidaemia in diabetes causes increased levels of low-
density lipoprotein (LDL) cholesterol and promotes atherogenesis (Bate and Jerums, 
2003). Hypertension is more common as is a hypercoaguable state. 
Retinopathy causes blindness in diabetic patients by causing hemorrhages and 
angiogenesis in the retina, resulting in damaged vision. Diabetes also accelerates 
cataract formation. Studies have suggested that eventually up to 75% of diabetic patients 
will develop retinopathy of some forms (Ewing et ai, 1998). 
Nephropathy is a syndrome of albuminuria, declining glomerular filtration rate 
and arterial hypertension that affects 20-40% of the diabetic patients (Ruggenenti and 
Remuzzi，2000). 
Neuropathy is a progressive deterioration of neuronal functions, resulting in 
peripheral and autonomic nerve dysfunction, causing painful syndrome, numbness, 
diarrhea, postural hypotension and erectile dysfunction (Watkins et aL, 2003). More 
than half of diabetic patients develop neuropathy (Feldman, 2003) and it is clear that 
impaired blood flow and endoneurial hypoxia are the major causes (Cameron et aL, 
2001). 
Foot ulcer and amputation are a major cause of morbidity, disability, as well as 
emotional and physical costs for diabetic patients (Frykberg et aL, 1998). About 15% of 
the patients will develop a foot ulcer at some point in their lives (Edmonds and Foster, 
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2004). Foot ulcer is associated with neuropathy and insufficient arterial supply. 
Infection also aggravates the ulcer condition (Calhoun et al., 2002). Current therapy of 
this complication is mainly by antibiotics and intensive wound care (Mason et al, 
1999). 
1.4. Current treatment of diabetes mellitus 
1.4.1. Type 1 diabetes 
Insulin injection is the major form of treatment of type 1 diabetes (Atkinson 
and Eisenbarth, 2001). Most individuals in developed countries are now treated with 
recombinant human insulin. Insulin analogues are also available for the treatment 
(Garg et al., 1999). Regular insulin needs to be given before meals (i.e., 30 minutes 
to 1 hour before) (Atkinson and Eisenbarth, 2001). 
Insulin therapy has improved the quality of life and extended the life 
expectancy of patients with type 1 diabetes (Rayat et al., 1999). Hypoglycaemia is 
the most common adverse effect of the insulin injection (Bolli, 1999). The major 
risk factor for severe hypoglycaemia is hypoglycaemia unawareness, which occurs 
particularly in patients with type 1 diabetes of long duration and in those with a 
history of frequent episodes of hypoglycaemia (Chiarelli et al” 1999). 
Islet transplantation is another treatment strategy for type 1 diabetes. Islet 
transplantation aims to overcome the lifelong need for daily insulin injections and 
frequent blood glucose testing, to promote maintenance of near normal blood 
glucose levels, and to avoid or even reverse the long-term diabetes-associated 
complications (Hirshberg et aL, 2003). However，the success rate of islet 
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transplantation is low. Failures are mostly due to chronic rejections and recurrence 
of autoimmunity. Also, the islet may be damaged by chronic immunosuppressive 
therapy (Lohmann et aL, 2002). 
1.4.2. Type 2 diabetes 
1.4.2.1. Diet and exercise 
Obesity is a strong predictor for type 2 diabetes. Even a modest degree of 
overweight can increase the risk of getting diabetes. Therefore, it is not surprising 
that dietary intervention, weight loss and exercises can effectively ameliorate the 
diabetic condition. Studies show that moderate weight loss and increased physical 
activity can increase insulin sensitivity (Kelley et aL, 2004; Jequier, 1984). From 
the Finnish study, it showed that the intensive lifestyle intervention in diet and 
exercise behaviour reduced diabetes risk and improved glycemia and lipemia 
(Lindstrom et aL, 2003). The Diabetes Prevention Program, which is a large, 
randomized clinical trial involving adults in the United States who were at high 
risk for the development of type 2 diabetes, also demonstrated that lifestyle 
intervention reduced the incidence of diabetes by 58% and metformin by 31% as 
compared with placebo, which showed that the lifestyle intervention was 
significantly more effective than metformin (Knowler et aL, 2002). 
1.4.2.2. Medication 
Generally, the above weight loss measures are insufficient or fail to control 
the diabetic condition. Therefore, medication is necessary for glycaemic control in 
type 2 diabetic patients. Medication for diabetes treatment not only aims at the 
pancreas but also the other tissues concerning glucose homeostasis, including 
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intestine, liver and peripheral tissues. Figure 1.2 illustrates the four target tissues and 
their respective mechanisms on diabetes treatment (Heine, 1999). The target 
mechanisms for a better glycaemic control in type 2 diabetes include: 
(1) Stimulation of insulin secretion from the pancreas; 
(2) Improvement in glucose transport into the peripheral tissues to improve 
insulin sensitivity of these tissues; 
(3) Reduction of the hepatic glucose production; 
(4) Inhibition of intestinal glucose absorption. 
By the medication, insulin resistance can be ameliorated by the 
improvement in peripheral glucose transport and the reduction of the hepatic glucose 
production. Stimulation of insulin secretion from the pancreas can improve both 
insulin resistance and impaired insulin secretion while inhibition of intestinal 
glucose absorption directly prevents the postprandial upsurge of blood glucose level. 
In the following sections, medications concerning these mechanisms are described in 
details. 
Apart from the above four mechanisms, there are some minor target 
mechanisms for diabetes treatment. For example, some drugs can increase the sense 
of satiety to the patients to control their appetite. 
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Retardation of intestinal glucose 
Lowering of hepatic glucose absorption, e.g. a-Glucosidase inhibitor 
production, e.g. Biguanides • 
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Stimulation in glucose transport, e.g. 
Thiazolidinediones 
Peripheral tissues 
Figure 1.2. The four major targets for type 2 diabetes treatment. The target 
mechanisms for glycaemic control in type 2 diabetes include stimulation of insulin 
secretion from the pancreas, improvement in glucose transport into the peripheral tissues， 
inhibition of the hepatic glucose production and inhibition of intestinal glucose 
absorption (Heine, 1999). 
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i. Sulphonylureas 
Sulphonylureas can stimulate pancreatic insulin secretion via specific 
sulphonylurea receptors on the pancreatic B-cells. Such binding results in 
depolarization of the plasma membrane and stimulates the release of insulin by 
moving the insulin-containing granules to the membrane (Chehade and 
Mooradian，2000). 
One of the most frequent side effects of sulphonylureas treatment is long-
term hypoglycaemia, which may cause neuronal defect or death. Another 
possible side effect is the body weight gain. 
ii. Biguanides 
The use of biguanides in diabetes treatment can be traced back to the use of 
Galega officinalis (goat's-rue or French lilac) as a treatment for diabetes in 
medieval Europe. Guanidine, which is the active compound of the plant, was 
used as the precursor to produce biguanides (Bailey and Day, 1989). The most 
commonly used biguanides in diabetic treatment in recent years is metformin 
(Figure 1.3). 
NH NH 
C H 3 \ II I 
. N — C — NH — C — NH2 
C H 3 / 
Figure 1.3. The structure of metformin. 
Metformin is an effective anti-hyperglycaemic agent, which lowers blood 
glucose mainly by inhibiting hepatic gkconeogenesis and therefore reducing 
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hepatic glucose output into the bloodstream (Crofford, 1995). To a lesser extent, 
metformin can also stimulate both basal and insulin-stimulated glucose uptake in 
the peripheral tissues, e.g. adipose tissue and skeletal muscle (Ciaraldi et aL, 
2002; Kumar and Dey, 2002). Lactic acidosis is a well recognized complication 
of biguanide therapy (Chan et aL, 1999). 
iii. Thiazolidinediones 
Thiazolidinediones is a new class of drug for the treatment of type 2 
diabetes. This class of drugs is shown to have an enhancing effect on insulin 
sensitivity by decreasing hepatic gluconeogenesis and increasing glucose uptake 
and metabolism in the peripheral tissues, especially skeletal muscles and adipose 
tissue (Wagstaff and Goa，2002). 
Troglitazone, the first thiazolidinediones available for clinical use, was, 
however, soon withdrawn from the market because of its hepatic toxicity. Its 
successors, rosiglitazone and pioglitazone, are found not to contain such toxicity 
(Isley, 2003). However, weight gain and increased LDL level are the adverse 
effects of thiazolidinediones treatment (O丨Moore-Sullivan and Prins, 2002). 
iv. a-Glucosidase inhibitor 
a-Glucosidase inhibitor can reduce postprandial glucose absorption from 
the intestine. Acarbose is the most commonly used a-glucosidase inhibitor 
clinically. Its structure is similar to the oligosaccharides, a digestion product 
from starch, and it is a reversible inhibitor of the digestive enzyme a -
glucosidase，which is present in the brush border of the small intestine. The drug 
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acts by competitively inhibiting the enzymes, thereby inhibiting the hydrolysis of 
oligosaccharides and disaccharides and hence delaying the absorption of glucose 
and other monosaccharides (Bischoff, 1994). 
There are some minor side effects with the use of a-glucosidase inhibitor, 
e.g. diarrhea, gas, bloating and abdominal/stomach pain. Although 
hypoglycaemia is rare, it may occur when it is used with other oral 
hypoglycaemic agent or insulin (Martin and Montgomery, 1996). 
V. Insulin injection 
Despite the former name of type 2 diabetes as "non-insulin dependent 
diabetes", about 40% of the type 2 diabetic patients actually require insulin 
injection to maintain normoglycaemia because their pancreas fail to produce 
insulin. These patients are mostly in the late-stage and other oral hypoglycaemic 
agents fail to rescue the situation. Hypoglycaemia is a major side effect of 
insulin therapy, which may occur before meal and at night (Campbell and White, 
2002). 
1 .5�The use of herbal medicines in diabetes treatment 
Before the discovery of insulin and the other drugs for treating diabetes, herbal 
medicines were the major form of treatment in the world. Even nowadays, in some 
developing countries and rural areas, these herbs are still the major form of diabetes 
treatment. These plants traditionally used for diabetes treatment can provide a source for 
the new anti-diabetic drug development (Bailey and Day, 1989). For example, the use of 
French lilac (Galega officinalis) in traditional diabetic treatment leads to the discovery 
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of biguanides (Witters, 2001). There are a number of plants traditionally used for anti-
diabetic treatment all over the world. However, only a few of them have been verified 
for their potency on diabetes treatment. Bitter gourd (Momordica charantia) has long 
been used in diabetes treatment in India. Research showed the water extract of bitter 
gourd could lower the blood glucose level in alloxan-induced diabetic rats (Virdi et al” 
2003). Other herbal materials, e.g. Panax Ginseng, onion bulb and garlic cloves, were 
also shown to have anti-diabetic effect based on systematic scientific researches (Bailey 
and Day, 1989). These examples demonstrate the potential of natural products to be 
incorporated into the medical systems as dietary supplements. 
In ancient China, although people had no clear concept of what exactly diabetes is, 
they developed their own system on the knowledge of the human body and they 
recognized diabetes as "Xiaoke" symptom (消渴症)，which is characterized by thirst, 
polyuria and weight loss. This symptom was described as early as 2000 years ago in 
"Huang Di Nei Jing"(黃帝内經，The Yellow Emperor's classic of internal medicine) 
and recognized as the results of inborn defects in the organs or disorder in diet (Ji，2000). 
Combinations of herbs or herbal formulae, instead of single herb, are usually prescribed 
for medicinal use in China and a number of Chinese herbal formulae are used to treat the 
disorder and ameliorate the symptoms. According to a brief review, Dang-Gui-Bu-Xue-
Tang (Dong Quai & Astragalus Combination,當歸補血湯)，Luwei-Dihuang-Fufang 
(Rehmannia Six Formula,六味地黃複方)，Si-Jun-Zi-Tang (Major Four Herb 
Combination,四君子湯）and Yu-Nu-Jian (Rehmannia & Gypsum Combination,玉女煎） 
are the common traditional Chinese medicine (TCM) formulae used to treat the 
"Xiaoke" symptom. Radix Astragali (黃耆），Radix Rehmanniae (生地），Radix 
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Trichosanthis (天花粉)，Rhizoma Coptidis (黃連)，Radix Ophiopogonis (麥冬)， 
Rhizoma Anemarrhenae (知母）and Radix Scrophulariae (玄參）are the common 
ingredients of these formulae (Wu and Ren, 2002). Some of them were studied for their 
anti-diabetic effects using scientific research methods and have shown anti-
hyperglycaemic effects in animal studies or in non-standardized clinical trials (Huang 
and Xu, 2002; Yang, 2003; Wang et aL, 2001). This implies that the traditional use of 
the Chinese herbs in treating diabetes is not only a folk legend. However, sufficient and 
concrete evidence on the efficacy and the safety, as well as the mode of action, of these 
herbs are still lacking. Therefore, in-depth studies on the anti-diabetic activities of these 
Chinese herbs are much needed. 
Two traditional Chinese medicine formulae, namely 托毒生肌顆粒齊J (Formula 1) 
and 耆味地黃顆粒劑(Formula 2)，were studied for their anti-diabetic effect on type 2 
diabetes. The anti-diabetic effects of the formulae, as well as their component herbs 
were tested because of several reasons: 
a) The formulae showed promising effect on healing the ulcer and over 80% of the 
patients were saved from amputation in a preliminary clinical study (Wong et aL, 
2001). We would like to explode the possibilities that the formulae and their 
individual components may possess anti-diabetic activities since glycaemic control 
of the foot ulcer patients is one of the effective ways to treat the ulcer. 
b) Some of the individual components in the formulae were found to be common 
ingredients of other anti-diabetic formulae, e.g. Radix Astragali and Radix 
Rehmanniae (Wu and Ren, 2002). It indicates that these herbs may possess anti-
diabetic activities. The anti-diabetic effects, as well as the mechanisms mediating 
such effects, can be confirmed through the investigations. 
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c) Since the patients taking these formulae for anti-ulcer treatment were also 
prescribed with modern anti-diabetic medications, and if these formulae have 
strong hypoglycaemic effect, it may cause undesired hypoglycaemia in the patients. 
This project focuses on the effects of formula 1 and its components. The details of 
formula 1 and its component herbs are discussed in Chapter 2. The effects of formula 2 
were studied by Mr. Lau Chun Hong (M.Phil candidate, the Institute of Chinese 
Medicine, The Chinese University of Hong Kong, another member of the AoE project). 
The effects of the formulae treatment on diabetic patients were also studied. Since the 
patients received both formulae treatment, it is impossible to differentiate the actions of 
each formula in the patients. 
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1.6. Hypothesis, objectives and design of the project 
Based on the fact that formula 1 and formula 2 showed promising effects on 
healing diabetic foot ulcer and some of the component herbs of formula 1 are used in 
traditional Chinese medicine for treatment of diabetes, it was hypothesized that formula 
1 and its component herbs possess anti-diabetic activities. 
The objectives of this project is to test the above hypothesis by conducting the 
following studies: 
1. Authentication of the component herbs in formula 1. 
2. Establishment of in vitro systems to screen for the herbs with potential anti-
diabetic effects. 
3. Establishment of an in vivo diabetic rat model to confirm the anti-diabetic 
effects of the herbs screened in objective 2. 
4. Investigation on the effects of formula 1 and formula 2 on glucose homeostasis 
in diabetic patients. 
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Chapter 2: Preparation and authentication of traditional 
Chinese medicines 
2.1 Introduction 
2.1.1 Background information of the formulae 
The two Chinese medicine formulae, originally designed for treating diabetic 
foot ulcer, were托毒生肌顆粒劑（formula 1) and耆味地黃顆粒劑（formula 2) 
and they consist of totally 12 individual herbs, including Radix Astragali (黃耆)， 
Radix Rehmanniae (生地)，Rhizoma Atractylodis Macrocephalae (白 jft), Radix 
Polygoni Multiflori Preparata (帝[j首烏),Rhizoma Smilacis Chinensis (蔬葜),Radix 
Stephaniae Tetrandra (漢防己)，Cortex Moutan (牡丹皮)，Fructus Schisandrae 
Chinensis (五味子)，Fructus Corni (山茱萸)，Rhizoma Alismatis (衝寫)，Rhizoma 
Dioscoreae (山藥）and Rhizoma Smilacis Glabrae (伏爷)• The two formulae were 
produced by water extraction of the raw herbal materials, followed by the spray-dry 
of the water extract. The formulae powders were produced by Hong Kong Institute 
of Biotechnology Limited (Hong Kong, China). 
From a previous study, the two formulae were shown to have successfully 
rescued over 80% of diabetic foot ulcer cases from amputation. Both formulae 
contain Radix Astragali and Radix Rehmanniae as the main ingredients. According 
to the traditional Chinese medicine principles, formula 1 and formula 2 serve 
different purposes at different stages of diabetic foot ulcer. Formula 1 aims to 
strengthen the muscle, control swelling, remove the debridement and promote 
granulation of the wound. Formula 2 aims to promote regeneration and healing of 
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the wound. Also, formula 2 can alleviate the diabetic symptoms, such as polyuria 
and thirst (Wong et al., 2001). 
In this project, not only the anti-diabetic activity of formula 1, but also that 
of its component herbs, was investigated. The features of each component herb in 
formula 1 and the extraction method are described in this chapter. 
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托毒生肌顆粒劑（Formula 1) 蓍味地黃顆粒劑(Formula 2) 
Radix Astragali ~ Radix Astragali ~ 
I t ^ ^ ^ 
Radix Rehmanniae Radix Rehmanniae ^ ^ 
生地 ^ ^ ^ 
Rhizoma Smilacis Chinensis Fructus Corni 
^ 山茱奥 9 二 
Rhizoma Atractylodis Macrocephalae Rhizoma Dioscoreae 
^ ^ im ^ 
Radix Polygoni Multiflori Preparata Fructus Schisandrae 
制首烏 ^ 五味子 ^ 
Radix Stephaniae Tetrandrae Rhizoma Alismatis 
漢防己 Lz ^ 
Rhizoma Smilacis Glabrae 伏爷 ^ Cortex Moutan 
牡丹皮 6g 
Table 2.1. The ingredients of formula 1 and formula 2. Each package contains 5g of 
the formula water extract powder, which was prepared from the raw herbal materials as 
indicated. The quantities of the raw herbal materials used are given in the table. 
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2.1.2 Component herbs of formula 1 
Formula 1 consists of 6 component herbs as listed in Table 2.1. More details 
of these herbs are described as follows. For their morphological details, please refer 
to section 2.3.1. 
a) Radix Astragali (黃耆) 
Radix Astragali is the root of Astragalus membranaceus (Fisch.) Bunge., or 
Astragalus mongholicus Bunge (family: Fabaceae). Radix Astragali is a commonly 
used medicinal herb in China and its functions and pharmacological actions have 
been well studied. This herb has immunomodulatory (Chu et al., 1988), anti-aging, 
diuretic, hypotensive (Chang and But, 1987), anti-bacterial, anti-tumor, skin-
reinforcing and tissue generative effects (State Administration of Traditional 
Chinese Medicine, 1999). The last two effects make this herb beneficial in curing 
diabetic foot ulcer. Radix Astragali can prevent insulin resistance (Lu et al., 1999). 
Moreover, Radix Astragali is the major component of many traditional anti-diabetic 
formulae, such as "Luwei Dihuang Fufang" (Rehmannia Six Formula,六味地黃複 
方）and "Fangji Huangqi Tang" (Stephania & Astragalus Combination,防己黃耆 
湯).It is believed that this herb has a beneficial effect on the diabetic condition. A 
recent study showed that one of the chemical compositions in Radix Astragali, 
named astragalus polysaccharides, possesses hypoglycaemic effect on diabetic rats 
(State Pharmacopoeia Commission, 2000). 
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b) Radix Rehmanniae (牛地) 
Radix Rehmanniae is the rhizome derived from Rehmannia glutinosa 
(Gaertn.) Libosch. (family: Scrophulariaceae). There are two forms of Radix 
Rehmanniae used as medicinal herbs, the uncured herb (生地）and the cured herb 
(熟地).The uncured form of herb was used in this project. A report showed that the 
alcohol extract of the water extract of this herb was able to lower the blood glucose 
in dogs. The herb also had a hypoglycaemic effect when given to rabbits by oral 
administration (State Pharmacopoeia Commission, 2000). It is also a main 
ingredient of the traditional anti-diabetic formula, "Luwei Dihuang Fufang" 
(Rehmannia Six Formula,六味地黃複方).Other effects of Radix Rehmanniae 
include improvement of hemorheology (Kubo et aL, 1994)，diuretic action, 
hepatoprotective activity and anti-inflammatory action (State Administration of 
Traditional Chinese Medicine, 1999). 
c) Rhizoma Smilacis Chinensis (菝葜) 
Rhizoma Smilacis Chinensis is the dried rhizome of Smilax china L. [S. 
japonica (Kunth) A. Gray]. It is usually used to treat rheumatic disease, dysentery 
and upset stomach (State Pharmacopoeia Commission, 2000). It is also found to 
have diuretic action and promotional effect on blood circulation (Liu et aL, 2002). 
No report concerning the effects of this herbal material on diabetes has been 
published. 
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d) Rhizoma Atractylodis Macrocephalae (白 jft) 
Rhizoma Atractylodis Macrocephalae is the rhizome of Atractylodis 
Macrocephalae Koidz. {Atractylodis ovata Thunb.) (family: Compositae). It is 
principally used in the treatment of poor appetite, dyspepsia, chronic diarrhea, 
edema and abnormal fetal movement (State Administration of Traditional Chinese 
Medicine, 1999). A few studies have been carried out on the anti-diabetic effect of 
Rhizoma Atractylodis Macrocephalae. Some researches showed that the herb only 
had a weak hypoglycaemic effect but the results were not conclusive (State 
Pharmacopoeia Commission, 2000). Other actions of Rhizoma Atractylodis 
Macrocephalae include diuretic, anticoagulant and tonic effects (Liu et al., 2000). 
e) Radix Polygoni Multiflori Preparata (葡1 首烏) 
Radix Polygoni Multiflori Preparata is the processed root tuber of Polygoni 
Multiflori Thunb. (family: Polygonaceae). The preparation process is done by 
mixing the slices of Radix Polygoni Multiflori with black bean juice, followed by 
stewing, steaming and drying under the sun (State Pharmacopoeia Commission, 
2000). This herb is famous for treating premature greying of the hair and easing off 
the aging process (Chen and Li, 1993). It is also used for promoting heart and 
vessels functions and lowering blood lipids and cholesterol level (Liu et al., 2000). 
No report concerning the effects of this herbal material on diabetes has been 
published. 
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f) Radix Stephaniae Tetrandrae (漢防H) 
Radix Stephaniae Tetrandrae is the dried tuber root of Stephaniae tetrandrae 
S. Moore (family: Menispermaceae). This Chinese folk medicine is used as an 
analgesic, diuretic, hypotensive and tuberculostatic agent (State Administration of 
Traditional Chinese Medicine, 1999). Radix Stephaniae Tetrandrae had not been 
investigated alone for its anti-diabetic activity. It is a major component of an anti-
obesity formula, Fangji Huangqi Tang (Stephania & Astragalus Combination,防己 
黃耆湯）.A study found that Radix Stephaniae Tetrandrae possesses anti-
hyperglycaemic effect on streptozotocin-diabetic mice and one of its components, 
fangchinoline, is responsible for such effect (Tsutsumi et al., 1993). 
2.2 Objectives 
This part aims to conduct the necessary studies prior to the investigation of the 
anti-diabetic effect of formula 1 as well as its component herbs. The six component 
herbs of formula 1 were authenticated according to their morphological characteristics 
and the authenticity of these herbs was further supported by thin layer chromatography 
(TLC). Then, water extraction of the herbs was performed. Lastly, the sugar contents of 
formula 1 and the component herb water extracts were determined by high performance 




2.3.1 Raw herbal materials and formula 1 extract 
a) Formula 1 (托毒生肌顆粒劑） 
Formula 1 was produced by the Hong Kong Institute of Biotechnology 
Limited (Hong Kong，China), under the Good Manufacturing Practice. Individual 
herbs were mixed and extracted by water under reflux. Solution was dried using 
spray-drier and stored in small packages in 5g and each package contains the 
amount of raw herbal materials as stated in Table 2.1. 
b) Traditional Chinese raw herbal materials 
Radix Astragali (黃耆)，Radix Rehmanniae (生地)，Rhizoma Atractylodis 
Macrocephalae (白 jft)，Radix Polygoni Multiflori Preparata (制J首烏)，Rhizoma 
Smilacis Chinensis (蔬葜）and Radix Stephaniae Tetrandra (漢防己），were 
purchased from Man On Long (Hong Kong, China). All of them were cultivated in 
China. The six component herbs of formula 1 were firstly authenticated by a 
morphological expert, Dr. Cao Hui (National Engineering Research Center for 
Modernization of TCM, Zhuhai, Guangdong, China). Figure 2.1 to Figure 2.6 show 
the morphology of the component herbs of formula 1. Herbarium voucher 
specimens were deposited at the museum of the Institute of Chinese Medicine, The 
Chinese University of Hong Kong, and their voucher specimen numbers are shown 




Figure 2.3. Morphology of raw materials of Rhizoma Smilacis Chinensis. 
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Figure 2.4. Morphology of raw materials of Rhizoma Atractylodis Macrocephalae. 
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Figure 2.5. Morphology of raw materials of Radix Polygoni Multiflori Preparata. 
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Figure 2.6. Morphology of raw materials of Radix Stephaniae Tetrandrae. 
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Chinese Herbs Voucher specimen numbers 
Radix Astragali 黃耆 2003-2457 
Radix Rehmanniae 生地 2003-2452 
Rhizoma Smilacis Chinensis 蔬葜 2003-2463 
Rhizoma Atractylodis Macrocephalae 白朮 2003-2458 
Radix Polygoni Multiflori Preparata 芾[|首烏 2003-2460 
Radix Stephaniae Tetrandrae 漢防己 2004-2526 
Table 2.2. The voucher specimen numbers of the six component herbs of formula 1. 
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2.3.2 Thin layer chromatography 
a) TLC plate 
TLC plates silica gel 60 F254 were purchased from Merck (Darmstadt, 
Germany). 
b) Reference compounds 
All the reference compounds (Figure 2.7) were purchased from the National 
Institute for the Control of Pharmaceutical and Biological Products (Beijing，China). 
i) Astragaloside IV is the reference compound of Radix Astragali (黃耆). 
ii) Catalpol is the reference compound of Radix Rehmanniae (生地). 
iii) Sarsasapogenin is the reference compound of Rhizoma Smilacis Chinensis ( 
蔬葜). 
iv) Fangchinoline and Tetrandrine are the reference compounds of Radix 
Stephaniae Tetrandra (漢防己). 
v) Aristolochic acid is the reference compound of Aristolochia fangi 
(廣防己)，the common adulterant of Radix Stephaniae Tetrandra. 
c) Reference herbs 
Reference herbs of Rhizoma Atractylodis Macrocephalae, Radix Polygoni 
Multiflori Preparata, Rhizoma Smilacis Chinensis and Radix Stephaniae Tetrandra 
and they were kindly provided by the Institute of Chinese Medicine, The Chinese 
University of Hong Kong. These reference herbs had been previously authenticated. 
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d) Solvents and Sprays 
Chloroform, methanol, ethyl acetate, acetonitrile and petroleum ether were 
purchased from Lab-Scan (Bangkok, Thailand). Acetone, phosphomolybdic acid, 
vanillin, potassium iodobismuthate and anisaldehyde were purchased from MERCK 
(Darmstadt, Germany). Sulphuric acid (H2SO4) was purchased from BDH 
Laboratory Supplies (Poole, United Kingdom). Absolute ethanol was purchased 
from Panreac (Barcelona, Spain). Acetic acid was purchased from Riedel-de Haen 
(Seelze, Germany). Anisaldehyde TS was freshly prepared from 0.5ml anisaldehyde, 
50ml acetic acid and 1ml sulphuric acid (State Pharmacopoeia Commission, 2000). 
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Figure 2.7. The reference compounds used in the TLC analysis of the herbs. (A) 
Astragaloside IV; (B) Catalpol; (C) Sarsasapogenin; (D) Fangchinoline; (E) Tetrandrine; 
(F) Aristolochic acid. 
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2.3.3 High performance liquid chromatography determination of 
the sugar content of the herbal extracts 
a) HPLC column 
Prevail Carbohydrate ES 5\i column (250 x 4.6mm) was purchased from 
Alltech Associates, Inc. (Deerfield, IL, USA). With the use of this column, D-
glucose, D-fructose，sucrose and L-rhamnose can be separated effectively. 
b) Carbohydrate standards 
D-glucose, D-fmctose and sucrose content in the herbal extracts were 
determined by HPLC method using L-Rhamnose (6-deoxy-L-mannose) as the 
internal standard (Figure 2.8). L-Rhamnose, D-Glucose, D-fructose and sucrose 
were purchased from Sigma (St. Louis, MO, USA). Around 50mg of L-rhamnose 
(accurately weighed out) was dissolved in 25ml of water, as the internal standard 
solution. D-Glucose, D-fructose and sucrose (around 20mg each, accurately weighed 
out) were mixed and dissolved in 25ml of water, as the stock solution. The stock 
solution was diluted to different concentrations according to the ratio shown in Table 
2.3. One millilitre of the standard solutions from the above dilution was added to six 
flasks respectively and 1ml of internal standard solution was added to each flask, 
and water was added to make up the volume of 10ml. 
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A) B) 
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H h c / " A H 
HO OH HO OH 
Figure 2.8. The structures of the sugar standards used in the HPLC analysis. 
(A) D-Glucose; (B) D-Fructose; (C) Sucrose; (D) L-Rhamnose, the internal standard. 
Volume ratio 
Stock solution 1 2 5 10 15 25 
Water 24 23 20 15 10 0 
Table 2.3. Dilution of HPLC stock solution. 
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c) Mobile phase 
Acetonitrile was purchased from Lab-Scan (Bangkok, Thailand). 
d) Herbal extracts preparation 
About lOmg of herbal aqueous extract (accurately weighed out) was 
dissolved in 10ml of water and 5ml of this solution was mixed with 1ml of L-
rhamnose internal standard solution. Lastly, water was added to make up the volume 
of 10ml. The solution was filtered by Millipore 0.45 jim filter to avoid the 
undissolved residues of the herbal extracts from blocking the HPLC column. The 
filtrate was then ready for HPLC analysis. 
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2.4 Methods 
2.4.1 Thin layer chromatography of the component herbs 
The TLC methods follow that are suggested by the Chinese Pharmacopoeia 
(State Pharmacopoeia Commission, 2000), except that the method used in Rhizoma 
Smilacis Chinensis preparation was modified from that suggested by 
Pharmacopoeia of the People's Republic of China (State Administration of 
Traditional Chinese Medicine, 1999). The TLC chromatograms of Rhizoma 
Atractylodis Macrocephalae (白 7ft) and Radix Polygoni Multiflori Preparata ($[!首 
烏）samples were compared to that of the reference herbs because their reference 
compounds were not commercially available. 
a) Preparation of herbal samples 
i) Radix Astragali (黃耆） 
About 3g of raw herb were grinded into powder and then refluxed with 20ml 
of methanol for an hour. The solution was filtered and the filtrate was evaporated. 
The residue was dissolved in 30ml of n-butanol and then extracted twice with 
20ml of water to remove the residual water-soluble fractions. Lastly, the n-
butanol solution was evaporated and the residue was dissolved in 0.5ml of 
methanol to make the testing solution. 
ii) Radix Rehmanniae (生地） 
About 2g of raw herb were grinded into powder and then refluxed with 20ml 
of methanol for an hour. The solution was filtered and the filtrate was collected. 
The filtrate volume was reduced to 5ml under reduced pressure using rotary 
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evaporator (Brinkmann, Westbury，NY, USA) and the concentrate was used as 
the testing solution. 
iii) Rhizoma Smilacis Chinensis (菝葜） 
About 5g of raw herb were grinded into powder and then refluxed with 50ml 
of ethanol for an hour. The solution was filtered and the filtrate was collected, 
then evaporated to complete dryness using rotary evaporator (Brinkmann, 
Westbury, NY, USA). The residue was refluxed with 20ml of 10% sulphuric acid 
for 3 hours. The solution was then extracted twice with chloroform. The 
chloroform layer was collected and evaporated to complete dryness using rotary 
evaporator (Brinkmann, Westbury, NY, USA). The residue was dissolved in 1ml 
of hexane as the test solution. The authentication of Rhizoma Smilacis Chinensis 
was also made by the reference herb, which was prepared under the same 
condition as the tested herb. 
iv) Rhizoma Atractylodis Macrocephalae (白 7[t) 
About 0.5g of raw herb were grinded into powder and then ultrasonicated 
with 2ml of n-hexane for 15 minutes. The solution was filtered and the filtrate 
was collected as testing solution. The authentication of Rhizoma Atractylodis 
Macrocephalae was made by the reference herb, which was prepared under the 
same condition. 
v) Radix Polygoni Multiflori Preparata (帝[]首烏） 
About 0.25g of raw herb were grinded into powder and then refluxed with 
50ml of ethanol for an hour. The solution was filtered and the filtrate was 
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collected. The filtrate volume was reduced to 3ml using rotary evaporator 
(Brinkmann, Westbury, NY, USA) under reduced pressure. The authentication of 
Radix Polygoni Multiflori Preparata was made by the reference herb, which was 
prepared under the same condition. 
vi) Radix Stephaniae Tetrandrae (漢防己） 
About Ig of raw herb were grinded into powder and dissolved in 6 drops of 
ammonia, followed by reflux with chloroform for 6 hours. The chloroform layer 
was retained and the chloroform was evaporated. The residue was dissolved in 
2ml of ethanol, as the testing solution. The authentication of Radix Stephaniae 
Tetrandrae was also made by the reference herb, which was prepared under the 
same condition. 
b) Preparation of reference compounds 
Reference compounds were dissolved in methanol to make up to Img/ml 
solutions. 
c) Thin layer chromatography 
The prepared herbal samples and the reference compound solution were 
spotted, using capillary tubes, on the baseline about 1cm from the bottom edge of the 
TLC plates, silica gel 60 F254. Ten milliliters of mobile phase was added to a covered 
glass chamber. After five minutes, the TLC plate was placed inside the pre-
equilibrated chamber to allow the capillary movement of the mobile phase. The plate 
was removed when the solvent front of the mobile phase reached about 1cm below 
the top edge of the plate and it was allowed to dry in the air. The TLC profiles were 
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detected and visualized using different methods. The mobile phases and the 
detection methods used for different herbs are listed in Table 2.3. The 
chromatograms of the tested were compared to that of the corresponding reference 






































































































































































































































































































































































































































































































2.4.2 Raw herbal materials water extraction 
For the water extraction of the raw herbal materials, 500g of the herbal 
materials were sliced into small pieces and boiled twice in 2L of distilled water 
for 2 hours under reflux system. The two parts of the aqueous extract were 
combined and filtered through a cotton cloth. The filtrate was then centrifuged at 
15,000 X g for 10 minutes. The supernatant was filtered through Whatman 55mm 
grade 1 filter paper (Whatman, Brentford, United Kingdom) to remove 
undissolved residue. The filtrate was frozen and then lyophilized into dry powder 
by a Thermo Savant MODULYO freeze-dryer (E-C Apparatus Corp., Holbrook， 
NY, USA) and the powder was stored in desiccator. The extraction product was 
weighed and the extraction yield was calculated. 
2.4.3 High performance liquid chromatography determination of 
the sugar content of the herbal extracts 
The sugar contents of the standard solution and the herbal extract samples 
were quantified by the use of HPLC-ELSD system. This determination is 
necessary because all plants contain high amount of carbohydrates, which serve 
as the structural components as well as energy source and storage. Since studies 
in this project focuses on glucose metabolism, the sugar content, especially 
glucose, in the herbal extracts may interfere with the in vitro and in vivo studies. 
Therefore, it is necessary to know the amount of sugars in herbal extracts. D-
glucose, D-fructose and sucrose content in the herbal extracts were determined 
because these simple sugars are the most abundant in plants. L-Rhamnose was 
used as the internal standard because it was not found in the herbal extracts. 
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Each determination was repeated for three times. The condition of the 
HPLC-ELSD system is shown in Table 2.5. The peak areas of different sugars 
were measured by 32 Karat Software version 5.0 (Beckman Coulter Fullerton， 
CA, USA). The peak area ratios of three sugar standards to the internal standard 
(e.g. peak area of D-glucose / peak area of L-rhamnose) were plotted against the 
concentration ratios of sugar standards to the internal standard (e.g. [D-glucose] / 
[L-rhamnose]) to obtain a calibration curve. The sugar concentration of the 
herbal extract sample was calculated by the peak area ratio of the corresponding 
sugar to L-rhamnose using the calibration curve. 
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HPLC Conditions 
Auto-sampler: Beckman System Gold 508 Autosampler 
Solvent pump: Beckman System Gold 125 Solvent Module 
Stationary phase: Alltech Prevail Carbohydrate ES 5|i Column (250mm x4.6mm) 
Mobile phase: Acetonitrile-Water (70:30) (v/v) 
Injection volume: 20)LI1 
Flow rate: Iml/min 
Running time: 20min for standards, 30min for testing solutions 
ELSD System 
Detector: Alltech ELSD 2000 
Temperature: 80�C 
Nitrogen gas flow: 2L/min 
Table 2.5. Conditions of HPLC-ELSD system for the determination of the sugar 
content in the herbal extracts. 
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2.5 Results 
2.5.1 Thin layer chromatography of the component herbs 
The six herbal components of formula 1 were authenticated by a 
morphological expert, Dr. Cao Hui，China, followed by further confirmation 
using thin layer chromatography (TLC) by comparing to the chromatograms of 
the reference compounds and/or reference herbs (Figure 2.9 to Figure 2.14). The 
spots on the chromatograms were identified by a value called retardation factor 
(Rf)*. 
Distance from baseline to centre of spot 
* Rf value = Distance from the baseline to the solvent front 
where 0 < Rf < 1. 
The tested herbs, except Radix Astragali, were found to contain 
compounds with the same Rf value of the corresponding reference compound 
(marked by the boxes), and/or have similar chromatogram patterns with the 
corresponding reference herbs. Therefore, the identities of these herbs were 
proven. The identity of Radix Astragali could not be confirmed by its TLC 
profile since a number of spots appeared at the position with Rf value of 0.19 (Rf 
value of Astragaloside IV) (Figure 2.9). The authenticity of Radix Astragali was 
supported by its morphological study. Since Radix Stephaniae Tetrandrae is 
commonly adulterated by aristolochic acid-containing Aristolochia fangi (Liang 
et al., 2000), the identity Radix Stephaniae Tetrandrae was further confirmed by 
the use of aristolochic acid in the TLC system. The tested Radix Stephaniae 
Tetrandrae sample was found to contain no aristolochic acid and the TLC profile 
of the tested samples matched that of the reference herb and the reference 
compounds. Therefore, Radix Stephaniae Tetrandrae was proven to be genuine. >t 
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a) Radix Astragali (黃耆） 
B) m n 
I邏 I 
象；h jyPMHHH 
/ ~ R f = o . i 9 I"' / I • ^ 擔 
1 2 1 2 
Figure 2.9. The TLC chromatograms of Radix Astragali under (A) visible light 
and (B) UV light (365nm). Lane 1 - Radix Astragali; Lane 2 - Astragaloside IV. 
Stationary phase: Silica gel 60 F254 
Mobile phase: Chloroform / methanol / water (13:7:2) (v/v) 
Detection method: Sprayed with 10% sulphuric acid in ethanol, heated at 110°C 
for 10 minutes 
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b) Radix Rehmanniae (生地） 
丨~ R f = 0 . 2 3 
tf^ R f = 0 . 2 3 
1 2 
Figure 2.10. The TLC chromatograms of Radix Rehmanniae under visible light. 
Lane 1 - Radix Rehmanniae; Lane 2 — Catalpol. 
Stationary phase: Silica gel 60 F254 
Mobile phase: Chloroform / methanol / water (14:6:1) (v/v) 
Detection method: Sprayed with anisaldehyde TS, heated at 105°C for 5 minutes 
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c) Rhizoma Smilacis Chinensis (蔬葜） 
•m 
t 
[ Rf = 0 .41 
\ R f = 0 . 4 1 
i • 
1 2 3 
Figure 2.11. The TLC chromatograms of Rhizoma Smilacis Chinensis under 
visible light Lane 1 - Rhizoma Smilacis Chinensis; Lane 2 - Rhizoma Smilacis 
Chinensis reference herb; Lane 3 — Sarsasapogenin. 
Stationary phase: Silica gel 60 F254 
Mobile phase: Chlorofomi / ethyl acetate (9:1) (v/v) 
Detection method: Sprayed with 7% ethanolic phosphomolybdic acid 
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d) Rhizoma Atractylodis Macrocephalae (白难） 
A) B) m ^ 
^mn^ • • • 
1 2 1 2 
Figure 2.12. The TLC chromatograms of Rhizoma Atractylodis Macrocephalae 
under (A) visible light and (B) UV light (365nm). Lane 1 - Rhizoma Atractylodis 
Macrocephalae; Lane 2 - Rhizoma Atractylodis Macrocephalae reference herb. 
Stationary phase: Silica gel 60 F254 
Mobile phase: Petroleum ether (60-90°C) / ethyl acetate (50:1) (v/v) 
Detection method: Sprayed with 5% solution of vanillin in sulphuric acid, heated 
at 105°C 
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e) Radix Polygoni Multiflori Preparata (制首烏） 
, B) m ^ m 
•mm'' 
Hi 
1 2 1 2 
Figure 2.13. The TLC chromatograms of Radix Polygoni Multiflori Preparata 
under (A) visible light and (B) UV light (365nm). Lane 1 — Radix Polygoni 
Multiflori Preparata; Lane 2 - Radix Polygoni Multiflori Preparata reference herb. 
Stationary phase: Silica gel 60 F254 
Mobile phase: Acetonitrile / water (25:75) (v/v) 
Detection method: Examination under UV light (365nm) 
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f) Radix Stephaniae Tetrandrae (漢防己） 
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Figure 2.14. The TLC chromatograms of Radix Stephaniae Tetrandrae under 
(A) visible light and (B) UV light (254nm). Lane 1 -Radix Stephaniae Tetrandrae; 
Lane 2 — Fangchinoline and Tetrandrine mixture standard; Lane 3 - Radix Stephaniae 
Tetrandrae reference herb; Lane 4 - Aristolochic acid. 
Stationary phase: Silica gel 60 F254 
Mobile phase: Chloroform / acetone / methanol / ammonia (20:3:2:0.1) (v/v) 
Detection method: Sprayed with 10% potassium iodobismuthate solution in 
dilute hydrochloric acid 
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2.5.2 Raw herbal materials water extraction 
The component herbs of formula 1 were extracted by water and the water 
extracts were freeze-dried to produce herbal water extract powder. The yield of 
extraction was calculated by dividing the weight of the herbal extract product by 
the weight of the raw herbal materials used for extraction. The percentage yield 
of extraction of each herb is shown in Table 2.6. The yield ranged from 10.10% 
(w/w) in Rhizoma Smilacis Chinensis to 48.10% (w/w) in Rhizoma Atractylodis 
Macrocephalae. Most of the herbs had an extraction yield above 20% (w/w). 





Rhizoma Smilacis Chinensis 
I S 1 0 .腦 
Rhizoma Atractylodis Macrocephalae 拟 ^^^ 
白 7ft ‘ 
Radix Polygoni Multiflori Preparata 
制首烏 21.33% 
Radix Stephaniae Tetrandrae 
漢防己 26.28% 
Table 2.6. Yield of extraction of the six individual herbal components of 
formula 1. Yield of extraction was calculated by the ratio of the weight of the 
extraction product to the weight of the raw herbal material used for extraction. 
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2.5.3 High performance liquid chromatography determination of 
the sugar content of the herbal extracts 
L-Rhamnose, out of a number of sugar standards tested, was chosen as 
the internal standard for the HPLC analysis because it was not found in the 
tested herbal extracts and its elution profile does not overlap with the target 
sugars. The retention time of L-rhamnose, D-fructose, D-glucose and sucrose 
were about 5min，6.1min, 7.3min and 9min respectively (Figure 2.15). A 
complete set of chromatograms is included in Appendix I. The calibration curves 
for each target sugar were plotted by the peak area ratios of the three sugar 
standards to the internal standard against the concentration ratios of sugar 
standards to the internal standard (Figure 2.16). The sucrose content of Radix 
Astragali extract was out of the range of the standard curve and therefore, the 
sucrose amount in Radix Astragali extract was determined after five-fold 
dilution. Since the calibration curve is not a straight line, it does not fit into the 
normal linear equation. Rather, it fits into the second-order polynomial equation 
in a single variable x, i.e. y 二 ax + bx + c, where y is the concentration ratio and 
X is the peak area ratio. The sugar contents of the herbal samples were 
determined by the corresponding standard curves. 
The amounts of D-glucose, D-fructose and sucrose in the herbal extracts 
are shown in Table 2.7. The results showed that Radix Astragali aqueous extract 
contains the highest sugar content, 55.52% w/w of its content was the three 
sugars and most of them were sucrose. Rhizoma Smilacis Chinensis, Radix 
Stephaniae Tetrandrae and Rhizoma Atractylodis Macrocephalae contain the 
least amount of sugars, about 12.14% w/w, 14.46% w/w and 13.66 w/w in total, 
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respectively, and the first two herbal extracts did not contain any sucrose. 
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Figure 2.16. Calibration curves of sugar standards. 
(a) D-Fructose: y = -0.0104x^ + 0.3678x + 0.1746，R^  = 0.9956; 
(b) D-Glucose: y = -0.0269x^+0.5246x + 0.1270，R^  = 0.9957; 
(c) Sucrose: y = -0.0284x^ + 0.5153x + 0.1134, R^ = 0.9967; 
where x-axis is the peak area ratio of the sugars to L-rhamnose and y-axis is the 
concentration ratio of the sugars to L-rhamnose. 
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Percentage of total herbal extract weight 
Herbal aqueous extracts (w/w) 
D-Fructose D-Glucose Sucrose Total 
Formula 1 6.53 2.06 7.23 19.36 
Radix Astragali (黃耆） 5.16 2.08 48.28 55.52 
Radix Rehmanniae (生地） 5.79 4.84 7.12 17.75 
Rhizoma Smilacis Chinensis < o � c ^o ^ . . 
, , , . o . o 3 5.32 0 12.14 
(拔葜) 
I^hizoma，metyio， 10.60 0.66 2.40 13.66 Macrocephalae (臼 7ft) 
Radix Polygoni MuMflori 9,52 8.49 17.99 36.00 
Preparata (制首烏） 
Radix Stephaniae Tetrandrae 7 22 7 24 0 14 46 
(漢防己） • • ’ 
Table 2.7. The content of D-glucose, D-fructose and sucrose in the herbal 
extracts. The sugar contents of the herbal extracts were calculated by the peak area 




In this chapter, the six herbal components of formula 1 were firstly 
authenticated according to their morphological characteristics by Dr. Cao Hui, a 
morphological expert. The identities of these herbs were further confirmed using thin 
layer chromatography (TLC) by comparing to the reference compounds and/or 
reference herbs. Although the proof from the TLC analysis of Radix Astragali was 
not strong, its identity was confirmed by its morphology. The identity of Radix 
Astragali can be easily distinguished by its texture, taste and cross-section from its 
counterfeits (Zhang, 2002). Radix Stephaniae Tetrandrae is commonly adulterated by 
Aristolochia fangi. Aristolochia fangi contains aristolochic acid, which causes 
nephropathy (Liang et al., 2000). Therefore, the identity of Radix Stephaniae 
Tetrandrae was further confirmed by the absence of aristolochic acid in the TLC 
analysis. 
TLC alone is not sufficient to prove the identity of a herb due to the possible 
overlapping content of the reference compounds present in different herbs. Moreover, 
chemical variability within the plant materials，as well as the fact that the growth and 
storage conditions and harvest and post-harvest processes can significantly affect the 
chemical composition of the herbal species and hinder the confirmation of its 
botanical identity (Hon et al., 2003). Therefore, TLC data were only used to support 
the morphological studies. For future studies, both microscopic study and HPLC 
analysis can be used to provide further evidence for the authentication of the herbs. 
After authentication, the herbs were extracted with water and then lyophilized 
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to produce herbal aqueous extract powder. Water extracts of the herbal materials 
were employed in this project because these Chinese herbs are traditionally taken 
through boiling the herbal materials in water, which resembles our present water 
extraction method. Moreover, formula 1 was made by the water extract of the 
ingredient herbs. Therefore, it is rational to use the water extracts instead of organic 
extracts for the subsequent investigation. However, a number of compounds in these 
herbal materials are non-polar compounds, such as alkaloids. Therefore, the use of 
water extraction method may inevitably lead to incomplete extraction of the 
compounds. The percentage yield of the extraction varied greatly among different 
herbs. The yield of Rhizoma Smilacis Chinensis was particularly lower than the 
others, which may be due to the fibrous nature of the plant (Ma, 2000). 
It is necessary to determine the sugar content in the extract because sugars may 
interfere with the in vitro and in vivo assays related to glucose metabolism and 
homeostasis. Sucrose is broken down into fructose and glucose in digestion. Glucose 
and fructose are then transported into the bloodstream by sodium-dependent glucose 
transporter 1 (Sgltl) and glucose transporter 5 (GlutS), respectively. Because D-
Glucose, D-fmctose and sucrose are the most abundant simple sugars in plants, the 
amounts of D-glucose, D-fructose and sucrose in the herbal aqueous extracts were 
determined by HPLC-ELSD system using L-rhamnose as internal standard. The 
details of the influence of the sugar content in the herbal extracts on the in vitro and 
in vivo investigation are discussed in Chapters 3 and 4. 
The glucose and fructose content in all extracts are generally low because these 
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two sugars are more commonly found in the fruits, where all of the component herbs 
are the root part of the plants. All the extracts generally contain high amount of 
sugars because the herbs were extracted with water, which can effectively extract 
polar compounds, such as carbohydrates. Carbohydrates other than glucose, fructose 
and sucrose present in the extracts may also affect the subsequent investigation of the 
anti-diabetic effects of the herbs. For example, starch, the most abundant 
polysaccharide for energy storage in plants, would probably interfere with the in vivo 
experiment because it is digested to glucose for absorption in the intestine. However, 
the quantification of the starch content in plants is more difficult and is beyond our 
present technical capacity. 
Comparison was made between the extraction yield and the sugar contents 
between formula 1 and its component herbs and it is shown in Table 2.8. It is found 
that the extraction yield of formula 1 preparation does not equal to that of the mixture 
of the component herbs preparation. Moreover, the theoretical contents of glucose 
and sucrose calculated from the sum of the sugar contents in the component herbs are 
higher than they should actually be in formula 1. The different extraction methods 
used in formula 1 preparation (spray-dry) and the component herbs preparation 
(freeze-dry) may account for such differences. Moreover, the differences in 
extraction yield and sugar contents may be due to the fact that the component herbs 
used in formula 1 preparation were different batches to those used in our herbal 
extract preparation. Different growth, storage，and processing can affect the chemical 
composition of the component herbs (Hon et aL, 2003). 
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In conclusion, the six component herbs of formula 1 were authenticated by 
their morphological characteristics and the authenticity of these herbs was further 
supported by their TLC profiles. Therefore, all the herbs used were proven genuine. 
Formula 1 and the extraction products of the herbal materials were then used in the 
subsequent experiments for the study of their anti-diabetic effects in vitro (Chapter 3) 








































































































































































































































































































































































































































































































































































Chapter 3: The anti-diabetic effects of formula 1 and its 
component herbs in vitro 
3.1. Introduction 
3.1.1. Glycaemic control in type 2 diabetes 
Normal blood glucose regulation is dependent on the feedback loop 
relationship among the liver, peripheral tissues (muscle and adipose tissue), and 
pancreatic islet cells (Kahn and Porte, 1996). However, the glucose homeostasis 
is disrupted in the diabetic state owing to insulin resistance and impaired insulin 
secretion. Impaired regulation of hepatic glucose production, peripheral insulin 
resistance and p-cell failure characterize the pathophysiology of type 2 diabetes 
mellitus (Mahler and Adler, 1999). These abnormalities are responsible for the 
fasting and postprandial hyperglycaemia in diabetes. The roles of individual 
malfunctions are discussed in the following sections. 
- Current treatments of type 2 diabetes are designed to target these 
abnormalities. As previously stated, there are four main mechanisms for the anti-
diabetic drugs to exert their effects to achieve glycaemic control (Heine, 1999) 
(Figure 1.2): 
(1) Stimulation of pancreatic insulin secretion; 
(2) Suppression of the hepatic glucose production; 
(3) Stimulation of glucose disposal in peripheral tissues; 
(4) Retardation of intestinal glucose absorption. 
The first three mechanisms obviously target the intrinsic impairments in 
diabetes. On the other hand, intestinal glucose absorption is not regulated in 
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normal glucose homeostasis and it shows no abnormality in the diabetic 
condition. Intestine is targeted in the treatment because type 2 diabetes is 
characterized by impaired glucose tolerance, causing a postprandial upsurge of 
blood glucose level (Davis et al., 1994). Theoretically，therefore，drugs that can 
retard the postprandial glucose upsurge may alleviate the adverse consequence of 
postprandial hyperglycaemia on the p-cell function and insulin sensitivity (Yki-
Jarvinen, 1992). Most of the current and developing drugs aim at the above 
mechanisms to exert their anti-diabetic effects. More details are given in section 
3.1.4. 
As the four mechanisms mentioned above are the main modes of action of 
the anti-diabetic drugs, formula 1 and its component herbs were firstly 
investigated for their effects on the target tissues in vitro. In this part, the herbal 
extracts were tested for their effects on the intestinal glucose absorption, hepatic 
glucose production and glucose transport into peripheral tissues (adipocytes and 
fibroblasts as model) (Figure 3.1). The detailed relationship between type 2 
diabetes and the target tissues, as well as the rationale of the in vitro assay 
systems, will be described in the following sections. 
68 
Intestine 
Lowering of / Retardation of glucose absorption 
-1 glucose production ^ H M W R V U H H 
Liver 
Stimulation of glucose uptake^^^^s^ 
Peripheral tissues 
Adipocytes & skin fibroblasts 
Figure 3.1. Three target mechanisms of the in vitro studies of the anti-diabetic 
effects of herbal extracts in the present study. The herbal extracts were tested for 
their effects on the in vitro systems on liver, intestine and peripheral tissues 
(adipocytes and fibroblasts as models). 
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3.1.2. Type 2 diabetes and peripheral tissues 
Glucose is the principal energy fuel of all the cells in the body tissues. 
Cellular glucose uptake also plays a crucial role in maintaining blood glucose 
homeostasis. Two insulin-responsive peripheral tissues are particularly important 
in maintaining this balance. They are skeletal muscle and adipose tissue 
(Bergman, 1997). When the blood glucose level is high, insulin is released from 
the pancreatic islet and stimulates these tissues to uptake more glucose for 
respiration or storage. These events promote glucose clearance from the 
bloodstream and maintain blood glucose at a steady level (Proietto et al., 1983). 
Nevertheless, insulin resistance in the diabetic condition results in diminished 
glucose uptake in these tissues (Summers et al., 1999). Apart from insulin-
stimulated glucose uptake, researches also found that the basal glucose uptake of 
these tissues is also lower than normal (Kahn, 2000). Therefore, it is believed that 
stimulation of both basal and insulin-stimulated glucose uptake of these insulin-
responsive tissues or even other insulin non-responsive tissues is beneficial to the 
amelioration of the diabetic state. 
In this part of the experiments, the effects of the Chinese herbs on 
regulating basal and insulin-stimulated glucose homeostasis in two peripheral 
tissue models were studied. Fibroblasts were used as the model for peripheral 
tissue regulating basal glucose homeostasis and it is usually regarded as insulin 
non-responsive tissue. Adipocytes were used as the model for peripheral tissue 
regulating insulin-stimulated glucose homeostasis and it is usually regarded as 
insulin responsive tissue. The effects of the herbal extracts on glucose uptake in 
these cells were studied. 
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Fibroblasts provide a convenient system to study the insulin independent 
glucose transport. Since the skin composes 15% of an individual's total body 
weight, a reduction of the glucose uptake into skin cells could indeed contribute 
to the increased glucose level in the blood (Gherzi et al, 1992). The glucose 
uptake in fibroblasts is mainly mediated via glucose transporter 1 (Glutl), while 
Glut3 is also present on the plasma membrane (Longo et al., 1992). Research has 
shown that high glucose level would decrease the glucose uptake as well as the 
proliferation rate of the skin cells (Spravchikov et al., 2001). In addition, the 
increase in the glucose uptake in this tissue may also increase the proliferation 
rate of the cells. This gives implications on the original purpose of formula 1，i.e. 
to treat the diabetic foot ulcer, because the skin fibroblasts in the ulceration area 
usually show a lower proliferation rate (Loots et al, 1999). 
Hs68 skin fibroblast cell line was chosen as the model because it is a 
normal skin fibroblast which resembles the skin tissues of the foot ulcer and its 
fast growth rate allows for rapid screening process. Moreover, skin fibroblast is 
regarded as an insulin non-responsive tissue and thus allows for the investigation 
of the effect of the herbal extracts on the basal glucose uptake. 
3T3-L1 adipocyte cell line was used as the model for insulin-responsive 
tissue. The major role of adipose tissue in the body is to act as an energy reserve, 
storing energy as lipids when the nutrients are abundant while releasing energy 
during fasting and starvation. The glucose uptake in adipocyte is mediated by 
both Glutl and Glut4. Glutl is responsible for the basal glucose transport while 
Glut4 is responsible for the insulin-stimulated glucose transport in the adipocytes 
(Harrison et al., 1992). Under resting state,- Glut4 localizes in the intracellular 
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vesicles. Insulin regulates glucose transport in adipocytes by triggering the 
translocation of the intracellular Glut4 to the cell surface (Hashiramoto and 
James，2000). In adipose tissue from normal subjects, insulin stimulates glucose 
uptake by approximately two-fold over the basal uptake level. Under the diabetic 
state, the adipose tissue in the diabetic patients is resistant to the insulin action. 
Therefore, the insulin-stimulated glucose uptake in the adipocytes is impaired 
when compared to normal. Moreover，the basal glucose uptake of the adipose 
tissue is lower than normal (Stolic et al., 2002). Some anti-diabetic drugs, e.g. 
thiazolidinediones, target insulin-responsive tissues to enhance their glucose 
transport and improve their insulin sensitivity (Martens et al.’ 2002). The 
increase in glucose transport plays a role in the glucose clearance from the 
bloodstream. Therefore, molecules that can enhance the glucose uptake of 
adipocytes may have beneficial effects on the diabetic state. 
3T3-L1 adipocytes were used as the model of adipocytes because it 
provides a simple and easy method for drug screening. When 3T3-L1 grows 
exponentially, the cells maintain fibroblast phenotype. Chemicals，such as 3-
isobutyl-l-methylxanthine (IBMX), dexamethasone (DEX) and insulin, can 
induce the differentiation of these cells into adipocytes. The morphology of 
adipocytes is different from that of the fibroblasts. Adipocytes show intracellular 
lipid accumulation (Wu et al” 1998). Fully differentiated 3T3-L1 adipocytes are 
responsive to insulin that glucose uptake is activated by insulin (Fong et al., 
1991). 
72 
The effects of the herbal extracts on cellular glucose uptake were 
measured (Hemati et al., 1997). This assay was conducted by pre-incubating the 
cells with herbal extracts, followed by the incubation of radioactive glucose 
analogue, 2-deoxy-D-glucose (2-DG). Then, the amount of the radioactive 2-DG 
transported into the cell was quantified. Glucose analogue, 2-deoxy-D-glucose, 
was used instead of glucose because it is not completely metabolized in the cells. 
2-deoxy-D-glucose undergoes phosphorylation inside the cells but goes no 
further in the glycolytic process (Navon et aL, 1989). 
3.1.3. Type 2 diabetes and liver 
The liver plays a central role in regulating glucose homeostasis through 
the control of glucose production. During fasting state, the liver is responsible for 
80% of the glucose release into circulation through glycogenolysis and 
gluconeogenesis (Stumvoll et al., 1997). The contribution of gluconeogenesis to 
overall hepatic glucose output increases rapidly with the duration of fasting, as 
glycogen store is depleted (Landau et al.’ 1996). In the postprandial state, hepatic 
glucose output is suppressed by nearly 80% (Selz et al., 2003). 
Insulin resistance in type 2 diabetes leads to the inability of insulin to 
control the activity of gluconeogenic enzymes, and hence, leads to the increase in 
hepatic glucose output and blood glucose levels (Barthel et aL, 2003). Several 
studies showed that the basal hepatic glucose production in the fasting state is 
elevated by about 30% in diabetic patients (Staehr et aL, 2002). In the 
postprandial state, suppression of hepatic glucose output is defective and about 
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50% of excessive glucose is produced by the liver in type 2 diabetic patients 
(DeFronzo, 1992). 
Owing to the importance of liver in glucose homeostasis regulation and 
the abnormalities of hepatic glucose metabolism found in type 2 diabetes, hepatic 
glucose production has been focused as the therapeutic target in diabetes. At 
present，the only approach that targets liver in diabetic treatment is the use of 
metformin (Stumvoll et al, 1995). Metformin primarily targets at the liver and 
results in 30% of reduction in basal hepatic output in diabetic patients (Perriello 
et al., 1994). Minor effects on inhibiting hepatic glucose output have also been 
reported in sulphonylureas and thiazolidinediones (Staehr et al., 2002). 
In this part, the effects of the herbal extracts on gluconeogenesis were 
studied. Gluconeogenesis is the formation of glucose from non-hexose precursors, 
such as lactate，glycerol and most of the amino acids, and it takes place mainly in 
the liver. This process is regulated by antagonistic insulin and glucagon through 
two rate-limiting enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase (G6Pase). The effects of the herbal extracts on PEPCK 
activity were also studied. The regulation of PEPCK has important impact on the 
glucose homeostasis. Transgenic mice with over-expression of PEPCK 
demonstrated diabetes phenotype with hyperglycaemia and impaired glucose 
tolerance (Valera et aL, 1994). Insulin inhibits basal PEPCK gene transcription. 
However, the PEPCK expression is not suppressed in diabetes (Sasaki et al, 
1984). Inhibitors of PEPCK such as metformin and troglitazone would reduce 
gluconeogenesis and hepatic glucose output, even in the presence of insulin 
resistance (Lochhead et al., 2001; Yuan et al.�2002; Davies et al., 1999). 
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The H4IIE rat hepatoma cell line was used as the model to study the 
effects of the herbal extracts on gluconeogenesis. H4IIE is derived from rat 
hepatoma (Pitot et al., 1964) with the expression of gluconeogenic enzymes 
including G6Pase and PEPCK, and the conservation of hormonal responsive 
properties to insulin (Sasaki et aL, 1984). Moreover, H4IIE hepatoma cells are 
unable to store glycogen and express glucokinase. The glucose produced by 
gluconeogenesis is not metabolized nor stored as glycogen (Riu et al” 1996). 
Therefore, H4IIE is commonly used as an in vitro model to study 
gluconeogenesis. 
The effects of the herbal extracts on gluconeogenesis were studied by two 
assays, glucose production assay and PEPCK assay. Glucose produced by the 
cells was measured by glucose oxidase method (Waltner-Law et al, 2002; Wang 
er aL, 2000). The herbs showing inhibitory effects on the glucose production 
assay were further studied in the PEPCK assay. 
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3.1A Type 2 diabetes and intestinal glucose absorption 
Carbohydrates are the major form of human diet. Glucose absorption 
from the intestine is the main element contributing to the postprandial glucose 
input into the bloodstream. In normal subjects，plasma glucose level increases to 
a peak, usually not exceeding 9mM，in 60-90 minutes after a carbohydrate-rich 
meal and gradually returns to pre-meal values by 3-4 hours. Through the action 
of insulin and glucagon, hepatic glycogen storage from glucose is stimulated 
(Taylor et al., 1996), hepatic glucose release is suppressed (Selz et al., 2003) and 
glucose disposal into skeletal muscle and adipose tissue is enhanced (Marin et al, 
1992) thus restores the plasma glucose level to normal rapidly. However，owing 
to the insulin resistance and impaired insulin secretion in type 2 diabetes, the 
above regulatory mechanisms are defected and this results in impaired glucose 
tolerance and causes postprandial hyperglycaemia (Gerich，1997). 
To control the postprandial blood glucose level, which is vital for the 
prevention of the complications associated with diabetes, it is important to limit 
the dietary intake of carbohydrates to prevent the postprandial spike of plasma 
glucose levels (Creutzfeldt, 1999). However, control by rigid diet restriction is 
not always possible. Pharmacological interventions that control carbohydrates 
digestion to release them gradually into the blood would be expected to benefit 
the patients (Creutzfeldt and Folsch, 1983). Acarbose, an a-glucosidase inhibitor, 
is used to control glucose absorption by competitively inhibiting the ability of a -
amylase and the a-glucosidase enzymes on the small intestinal brush border to 
break down oligosaccharides and disaccharides into monosaccharides (DeFronzo, 
1999). 
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Beside a-glucosidase inhibitor，there are other possibilities to control the 
intestinal glucose absorption to prevent the postprandial blood glucose spike, 
such as inhibition of Na+-dependent glucose transporter 1 (Sgltl) (Wagman and 
Nuss，2001). Sgltl is responsible for the absorption of glucose from the intestinal 
lumen into the bloodstream. It co-transports D-glucose and sodium ion across the 
intestinal brush border membrane, with the stiochiometric ratio of sodium ion to 
D-glucose 2:1 (Semenza et al., 1984). 
To examine the effects of the herbal extracts on the Sgltl，a model called 
brush border membrane vesicles (BBMV) was used. BBMV are spherical 
vesicles prepared from the apical membrane microvilli of rabbit intestinal 
enterocytes (Schmitz et al., 1973. Kessler et al, 1978) and Sgltl is located on the 
membrane. The outer surface represents the intestinal lumen and the core of the 
vesicle represents the intestinal cell. Over 90% of BBMV have the correct 
orientation, by the interior representing the serosal side (Haase et al., 1978). The 
advantage of using BBMV in such studies is that Sgltl-mediated glucose 
transport can be studied without the interference from glucose transporter 2 
(Glut2) which locate on the basolateral membrane of the enterocytes 
(Vedavanam et al., 1999). 
To study the effect of the herbal extracts on intestinal glucose absorption 
in vitro, glucose uptake assay on BBMV was performed (Hopfer et al., 1973). In 
the BBMV glucose uptake experiment, the BBMV were incubated with the 
herbal extract and the radioactive glucose. Since the final glucose concentration 
in the BBMV mixture is very low (0.067mM), any trace amount of glucose 
present in the herbal water extracts would compete with the radioactive glucose 
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for the Sgltl and hinder the uptake of the radioactive glucose. Therefore, 
chloroform extraction on the herbal water extracts was used to remove glucose in 
the water extracts. However, other polar compounds were inevitably excluded. 
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3.2. Objectives 
In this part, formula 1 and its component herbs were tested for their effects on 
tissue glucose homeostasis through four in vitro systems (Figure 3.1). The objectives 
of this part of the project are: 
1’ Testing herbal extracts for their effects on glucose transport in 3T3-L1 
mouse adipocytes and Hs68 human skin fibroblasts, which were used as the 
models of insulin-responsive and insulin non-responsive peripheral tissues, 
respectively. 
2. Testing herbal extracts for their effects on glucose production in H4IIE rat 
hepatoma cells, which were used as the in vitro model of liver 
gluconeogenesis. 
3. Testing herbal extracts for their effects on BBMV glucose uptake, which 




All cell lines were purchased from American Type Culture Collection (ATCC) 
(Manassas，VA, USA), all chemicals were purchased from Sigma (St. Louis, MO, 
USA) and all culture media, serum supplements and antibiotic mixture solution were 
purchased from Gibco BRL Life Technologies, Inc. (Carlsbad，California, USA) 
unless otherwise indicated. 
3.3.1. Cell lines 
a) 3T3-L1 mouse fibroblasts (Chemically induced to adipocytes) 
3T3-L1 (ATCC CL-173) is a mouse embryonic fibroblast cell line，which 
is isolated from Swiss albino mouse and an infinite substrain of 3T3-Swiss albino 
cell line. Cells can undergo a pre-adipose to adipose-like conversion as they 
progress from a rapidly dividing state to a confluent and contact inhibited state or 
by chemical induction. 
b) Hs68 human fibroblasts 
Hs68 (ATCC CRL-1635) is a human fibroblast cell line. It is one of a 
series of human foreskin fibroblast lines obtained from normal Caucasian 
newborn male. 
c) H4IIE rat hepatoma cells 
H4IIE (ATCC CRL-1548) is a rat hepatoma cell line. The H4IIE 
hepatoma cell line has been used by many investigators to study insulin action 
because insulin can act on these cells at picomolar concentrations to induce many 
effects normally associated with growth factors (Schwartz，1993). 
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3.3.2. Cell culture media, buffers, reagents and culture wares 
a) Cell culture media 
i) Dulbecco's modified Eagle medium (DMEM) 
The powder form of DMEM medium supplemented with 4,500mg/L of 
D-glucose, 4mM of L-glutamine，and llOmg/L of sodium pyruvate and 
4mg/L of pyridoxine HCl, was used for the preparation of culture medium. 
The powder was dissolved in double distilled water and buffered with 3.7g of 
sodium bicarbonate (NaHCOs) per litre. The pH value of the medium was 
adjusted to 7.2 to 7.4 by 6M hydrochloric acid (HCl) and the medium was 
sterilized by filtration through a 0.22fxm Millipore filter (Millipore, Billerica， 
Mass, USA) and stored at 4°C until use. 
ii) Dulbecco's modified Eagle's medium (DMEM, without glucose) 
The liquid form of no glucose DMEM medium supplemented with 4mM 
L-glutamine was used for experiment of 3T3-L1 and Hs68 cell lines. It was 
stored at 4°C until use. 
iii) Dulbecco's modified Eagle's medium (DMEM, without glucose and 
phenol red) 
Glucose-free Dulbecco's modified Eagle's medium was purchased from 
Sigma (St. Louis, MO, USA). It contains no phenol red，glucose, sodium 
pyruvate and sodium bicarbonate. The preparation and the storage of this 
medium was the same as the standard Dulbecco's modified Eagle medium. 
This medium was used in the glucose production assay and PEPCK assay in 
H4IIE cells. 
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b) Serum supplements 
Fetal bovine serum (FBS) was stored as 50ml aliquots in sterile centrifuge 
tubes and the aliquots were then kept frozen at - 7 0 � C until use. 
c) Antibiotic mixture solution 
Penicillin-Streptomycin (PS) antibiotic mixture stock solution containing 
lOOOOunits/ml of penicillin G sodium plus 10000|Lig/ml of streptomycin sulphate 
in 0.85% saline was stored as aliquots of 10 ml in sterile centrifuge tubes at -
70°C. 
d) Complete medium 
DMEM (high glucose) medium supplemented with 10% (v/v) FBS and 
1% (v/v) PS was used for sub-culturing of all the studied cell lines. 
e) Phosphate-buffered saline (PBS) 
Stock PBS solution (lOx) was prepared by dissolving 80g of sodium 
chloride (NaCl)，2g of potassium chloride (KCl), 14.4g of dibasic sodium 
phosphate (NazHPCU • 2H2O), 2.4g of monobasic potassium phosphate (KH2PO4 
• H2O) in one litre of double distilled water with pH calibrated to 7.4 by 6M HCl 
or 2M sodium hydroxide (NaOH). A working solution (Ix) was prepared by 
diluting 100ml of lOx PBS (warm before use) with 900ml of double distilled 
water and then sterilized by autoclaving at 121�C for 20 minutes. It was stored at 
4°C until use. 
•-t 
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f) Trypsin-EDTA Solution 
Trypsin-EDTA solution (without C a " and Mg2+) containing 0.05% (w/v) 
trypsin and 0.53mM of EDTA-tetrasodium in Hank's balanced salt solution was 
stored at —70�C as 50 ml aliquots until use. 
g) Cell Culture Wares 
Glasswares used for sub-culture and experiments, including flasks，multi-
well plates and centrifuge tubes, were all purchased from Iwaki (Chiba, Japan). 
3.3.3. Chemicals, media and reagents for 3T3-L1 differentiation 
a) 3-Isobutyl-l-methyIxanthme (IBMX) 
IBMX powder was dissolved in 0.5M of potassium hydroxide (KOH) as a 
stock solution of 50mM. The solution was sterilized by passing through a 0.22|Lim 
filter and stored as 1ml aliquots at -20°C. 
b) Dexamethasone (DEX) 
DEX powder was dissolved in 100% ethanol as a stock of ImM and 
stored at -20°C as freezer stock. Working stock was prepared by diluting the 
freezer stock to O.lmM in sterile PBS and stored at 4�C. 
c) Insulin 
Insulin solution (bovine origin) (lOmg/ml) was stored at 4�C. 
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d) Oil red O 
Oil red O stock solution was prepared by dissolving excess oil red O 
powder in isopropanol to constitute a saturated solution. This stock solution was 
stored under dark. The working solution was prepared by diluting the stock 
solution with distilled water at the volume ratio of 3:2 and it was allowed to stand 
at room temperature for 7-10 minutes. The solution was then filtered immediately 
before use. 
e) IBMX-DEX-Insulin cocktail medium for 3T3-L1 differentiation. 
IBMX-DEX-Insulin cocktail medium was freshly prepared for 3T3-L1 
differentiation. The cocktail medium was prepared by supplementing the 
complete high-glucose DMEM to the final concentration of 0.5mM of IBMX, 
0.5fiM of DEX and 5|ig/ml of insulin. The chemicals were freshly added to the 
medium before use. 
f) Insulin-supplemented medium 
Insulin-supplemented medium was freshly prepared for 3T3-L1 
differentiation. The medium was prepared by supplementing the complete high-
glucose DMEM to the final concentration of S^ig/ml of insulin. 
3.3.4. Chemicals and reagents for 3T3-L1 and Hs68 2-deoxy-D-
glucose (2-DG) uptake assay 
a) 2-Deoxy-D-[l-^H]glucose 
The stock solution (ImCi/ml, 14Ci/mmol) was obtained from Amersham 
(Little Chalfont，United Kingdom) and stored at 4°C. 
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b) 2-Deoxy-D-glucose (2-DG) 
2-Deoxy-D-glucose solution was prepared by dissolving 0.821g of the 
powder in 500ml of PBS to the concentration of lOmM and stored at 4�C. 
c) Liquid scintillation cocktail 
The OptiPhase HiSafe 2 scintillation fluid (PerkinElmer Life sciences, 
Inc.，Boston, MA, USA) was stored in the dark at room temperature. 
3.3.5. Chemicals and buffers for H4IIE glucose production assay 
and phosphoenolpyruvate carboxykinase (PEPCK) assay 
Insulin and dexamethasone were used in these assays and they were 
prepared and stored as previously described. 
a) 8-(4-ChIorophenylthio)adenosine 3'，5-cyclic monophosphate sodium 
salt (pCPT-cAMP) 
pCPT-cAMP powder was dissolved in distilled water to a concentration 
of 5mM and stored as 1ml aliquots at 4°C. 
b) Glucose production buffer 
Glucose production buffer was prepared by DMEM solution (without 
glucose and phenol red) (see Section 3.3.2 (a)(iii)) supplemented with 5mM of 
sodium pyruvate and 50mM of sodium lactate. 
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c) Lysis buffer for PEPCK assay 
Lysis buffer contained 20mM of Tris-HCl, 50mM of potassium chloride 
(KCl)，5mM of magnesium chloride (MgCh), 2mM of EDTA, ImM of 
dithiothreitol (DTT) and 1% polyethylene glycol and the pH was adjusted to 6.6. 
d) Assay buffer for PEPCK assay 
Assay buffer contained llOmM of imidazole-HCl, 45mM of NaHCOs, 
2mM of phosphoenolpyruvate, 3mM of MgSCU, 3mM of manganese chloride 
(MnCl2)，13mM of sodium fluoride (NaF), ImM of DTT, 0.5mM of GDP, 0.15mM 
of NADH and 6 units of malate dehydrogenase, and the pH was adjusted to 6.8. 
e) Enzymatic-spectrophotometric glucose oxidase/peroxidase assay kit 
Enzymatic-spectrophotometric glucose oxidase/peroxidase assay kit was 
purchased from Biosystems S.A.，Spain. The assay kit includes a bottle of assay 
reagent, containing 70mmol/L of phosphate, 5mmol/L of phenol，more than 
lOU/ml of glucose oxidase, more than lU/ml of peroxidase, 0.4mmol/L of 4-
aminoantipyrine, at pH 7.5, and a bottle of glucose/urea/creatinine standard, 
containing lOOmg/dl (5.55mmol/L) of glucose, 50mg/dl of urea，2mg/dl of 
creatinine. 
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3.3.6. Animal，buffers and reagents for preparation and glucose 
uptake assay of brush border membrane vesicles (BBMV) 
a) Animal 
White New Zealand rabbits were obtained from The Laboratory Animal 
Services Centre, The Chinese University of Hong Kong. 
b) Buffer 1 
Buffer 1 contained lOmM of D-mannitol, 2mM of Tris (USB Corp, 
Cleveland, OH, USA) and the pH was adjusted to 7.1 by 125mM of HEPES. 
c) Buffer 2 
Buffer 2 contained lOOmM of D-mannitol, O.lmM of MgSO*，2mM of 
Tris and the pH was adjusted to lA by 125mM of HEPES. 
d) Buffer 3 
Buffer 3 contained 300mM of D-mannitol, O.lmM of MgSOg, lOmM of 
Tris and the pH was adjusted to 7.4 by 125mM of HEPES. 
e) Stop-wash buffer 
The stop-wash buffer contained 200mM of NaCl, lOmM of HEPES-Tris 
and 250|LIM of phlorizin (other names: phlorhizin, phloridzin). Phlorizin is a 
Sgltl inhibitor used to stop the glucose uptake by the BBMV. 
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f) D-[2-^H]glucose 
The stock solution (ImCi/ml，15-20Ci/mmol) was obtained from 
Amersham (Little Chalfont, United Kingdom) and stored at 4 � C . 
3.3.7. Reagents for bicinchoninic acid (BCA) protein assay 
a) Bicinchoninic acid 
Bicinchoninic acid was stored at room temperature. 
b) Copper (II) sulphate pentahydrate solution 
Copper (II) sulphate pentahydrate was prepared as a 0.16M solution and 
stored at room temperature. 
c) Bovine serum albumin (BSA) 
BSA standard was prepared as lOmg/ml stock in autoclaved double 
distilled water and stored as 1ml aliquots at —20°C. 
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3.4. Methods 
3.4.1. Cell culture 
3T3-L1 mouse fibroblasts, Hs68 human fibroblasts and H4IIE rat 
hepatoma cells were cultured in complete high-glucose DMEM (contained 10% 
(v/v) FBS and 1% (v/v) PS (final concentration: lOOunits/ml of penicillin G 
sodium and 100|Lig/ml of streptomycin)). The cultures were kept at 37�C, 5% CO2 
atmosphere in a humidified condition. The medium was changed twice or three 
times a week and subcultured when the cell density reached 70%. 3T3-L1 was 
maintained between and IS^ *" passages for experiments. Hs68 and H4IIE were 
maintained between and 20出 passages for experiments. 
For the subculture procedure, medium was first removed and the adherent 
cells were rinsed once with pre-warmed PBS before mild trypsinization with 1ml 
(for 15cm culture flask) or 2ml (for 150cm^ culture flask) of trypsin-EDTA 
solution at 37°C for 2-3 minutes. Then, 10ml of fresh medium was added to stop 
trypsinization when all the cells were detached from the culture flask. Cells were 
then collected by centrifugation at 200 x g for 3 minutes at 25 °C. Following re-
suspension in fresh medium, appropriate aliquots of cell suspension were 
aspirated and dispensed into a new culture flask with fresh medium (15ml for 
IScra flask or 25ml for 150cm^ flask). 
Long-term storage of cell line was performed by cryo-preservation in 
liquid nitrogen. Cells were allowed to grow until 80% confluence and 
trypsinized as described previously. The cell pellet was re-suspended in 1ml (for 
75cm^ culture flask) or 2ml (for 150cm^ culture flask) of fresh medium. Then, 
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1ml of cell suspension was dispensed into pre-labelled cryogenic vial with 10% 
cryoprotectant dimethyl sulphoxide (v/v) (Sigma, St. Louis, MO，USA). The 
vials were placed in a Nalgene freezing container at -70°C freezer to achieve 
rC/minute cooling rate. After an overnight incubation, the vials were 
transferred to liquid nitrogen freezer. 
3.4.2. Studies on glucose uptake in 3T3-L1 adipocytes and Hs68 
fibroblasts 
3.4.2.1 Differentiation of 3T3-L1 cells 
3T3-L1 fibroblast cells were chemically induced into differentiated 
adipocytes before glucose uptake experiments as previously described (Hemati et 
al” 1997)，with modifications. Briefly, cells were seeded on the 24-well plates 
and they were maintained until confluent state. Two days after confluence (set as 
day 0), the medium was switched to IBMX-DEX-Insulin cocktail medium. On 
day 3, the medium was switched to the insulin-supplemented medium. After two 
days，the medium was then switched to normal complete medium and the 
medium was changed every 2 days. About 90% of the cells showed an adipocytes 
phenotype of lipid droplets accumulation shown by oil red O staining. The cells 
were used in experiments on day 9-12 after start of the differentiation. 
3.4.2.2 Oil red O staining of the 3T3-L1 cells 
The cells were fixed with 2% paraformaldehyde (Sigma, St. Louis, MO, 
USA). Oil red O working solution was added to the cells and it was allowed to 
stand at room temperature for 10-15 minutes. The cells were then washed 
extensively with PBS and the cells were observed under light microscope. 
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3.4.2.3 2-DG uptake assay of 3T3-L1 adipocytes and Hs68 fibroblasts 
The assay was performed as described by Jarvill-Taylor et al (2001). 
Differentiated 3T3-L1 cells seeded in 24-well plates were rinsed once with PBS 
buffer. Then, the cells were serum-starved with plain high-glucose DMEM 
(without FBS and PS) for 2 hours. Selected concentrations of TCM water extracts 
were prepared by dilution in glucose-free DMEM and then filtration through a 
0.22^im filter. The cells were incubated with different concentrations of herbal 
extracts at 37°C for 30 minutes. Negative control experiment was set up by 
incubating the cells with plain high-glucose DMEM only. Positive control 
experiment was set up by incubating the cells with lOOnM of insulin in plain 
high-glucose DMEM. The herbal extracts were removed by washing with PBS 
for 3 times. Then, 300^1 Hot/Cold mixture containing of 2^Ci/ml 2-deoxy-D-[l-
^H]glucose, O.lmM of 2-DG in glucose-free DMEM were added and the reaction 
was allowed to proceeded for 15 minutes at 37°C. The reaction was stopped by 
adding Iml/well of ice-cold lOmM of 2-DG in PBS solution and each well was 
washed by the same solution twice. Then, 200fxl of 0.5M NaOH was added to 
lyse the cells. The plates were put on the orbital shaker for 10 minutes to ensure 
complete lysis and 200^1 of 0.5M HCl was then added to neutralize the alkaline. 
300fil of the cell lysate was transferred to scintillation vial and 4ml of OptiPhase 
HiSafe 2 scintillation fluid was added to each sample and radioactivity in aliquots 
was determined by a Packard Tri-Carb® 2900TR liquid scintillation counter 
(PerkinElmer Life Science Inc, Boston, MA, USA). 
For the glucose uptake assay of Hs68 fibroblasts, cells were seeded in 
24-well plates to a confluent state and the glucose uptake assay was performed 
two days later. The experiment procedure was identical to the 2-DG uptake assay 
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of 3T3-L1 cell except the followings: Cells were glucose-starved by DMEM 
without glucose for 1 hour prior to the uptake assay; 100…of 0.5M NaOH 
followed by lOOfxl of 0.5M HCl were added to lyse the cells; and 120fxl of the 
cell lysate was transferred to scintillation vial for radioactivity determination. 
In each glucose uptake experiment, a "non-specific binding" set-up was 
performed. The incubation procedure was the same as the control experiment, 
with the exception that the addition of radioactive 2-DG was immediately 
followed by the washing steps. This set-up aimed to determine the non-specific 
binding of the radioactive 2-DG on the cell membrane surface，not the glucose 
that was transported into the cells. 
The amount of glucose uptake was corrected by protein concentration, 
which is determined by BCA protein assay described in section 4.4.5. Glucose 
uptake was calculated as amount of glucose uptake in dpm per milligram of 
protein. The corrected glucose uptake was subtracted by the non-specific binding 
value. Results were expressed as the percentage of glucose production of 
negative control. 
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3.4.3. Studies on gluconeogenesis in H4IIE hepatoma cells 
3.4.3.1 Glucose production assay 
The glucose production assay was conducted based on the method 
described in Waltner-Law et al (2002) and Wang et al (2000). Briefly, 1.2 x 10^ 
cells were seeded in 90mm dishes. After growing for two days，medium was 
replaced by medium containing 500nM of DEX and O.lmM of pCPT-cAMP. It 
served as the negative control. In treatment groups, herbal extracts were added to 
the DEX/pCPT-cAMP supplemented medium to the final herbal extract 
concentration of 0.04, 0.2, 1 or 5 mg/ml. For the positive control group, insulin 
was added to the DEX/pCPT-cAMP supplemented medium to the final insulin 
concentration of lOnM. After five-hour incubation, medium was removed and 
dishes were washed three times with PBS. Then, 2ml of glucose production 
buffer was added and incubated with the cells for 3 hours. The glucose 
concentration of the glucose production buffer was determined by an enzymatic-
spectrophotometric glucose oxidase/peroxidase assay kit with modification. 
Briefly, 1ml of glucose production buffer was mixed with 0.3ml glucose assay 
solution at 37°C for 5 minutes. Absorbance at 500nm was recorded. The protein 
concentration of each sample was also determined. Dishes were washed with 
PBS and cells were lysed by 5ml 0.5M of NaOH for 10 minutes. The lysate was 
neutralized with 5ml 0.5M of HCL Protein content of samples were determined 
by BCA assay, as described in section 4.4.5. The amount of glucose production 
was corrected by protein concentration. Results were expressed as the percentage 
of glucose production of negative control. 
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3.4.3.2 PEPCK assay 
PEPCK assay was conducted according to previously described 
methods (Wiese et al., 1991). By the addition of excessive NADH， 
phosphoenolpyruvate and malate dehydrogenase, PEPCK activity was 
determined by the rate of NADH consumption using spectrophotometric method 
(Figure 3.2). 
Phosphoenolpyruvate 
PEPCK NADH NAD+ 
Oxaloacetate • Malate 
Malate dehydrogenase 
Figure 3.2. The PEPCK activity of the H4IIE hepatoma cells was detected by 
the rate of NADH consumption. The H4IIE cell lysate was supplied with excessive 
NADH, phosphoenolpyruvate and malate dehydrogenase. The rate of NADH 
consumption, therefore, represents the PEPCK activity in the cell lysate. 
Briefly, cells were seeded in the 90mm dishes and treated as described 
in the glucose production assay until after five-hour incubation of DEX/pCPT-
cAMP supplemented medium, with or without herbal extract treatment. Negative 
control experiment and positive control experiment were established in the same 
condition as in the glucose production assay. After incubation, medium was 
removed and dishes were washed with PBS twice. Then, 200\il of lysis buffer was 
added to each dish. Cells were scrapped off, lysed with sonication and centrifuged 
at 15000 X g for five minutes. Pellets were discarded. Then, SOjul of supernatant 
was mixed with 500|li1 PEPCK assay buffer to measure the PEPCK activity. 
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Absorbance at 340nm of the mixture was monitored for one minute at 15-second 
intervals. Rate of absorbance change was recorded. Protein content of supernatant 
was determined by BCA assay. Absorbance change was divided by protein 
content. PEPCK activity of each sample was expressed as percentage of negative 
control. 
3.4.4 Studies on BBMV glucose uptake 
3.4.4.1 Preparation of BBMV 
BBMV were prepared based on the Mg2+ precipitation method proposed 
by Schmitz et al (1973) and the modifications of Kessler et al. (1978). Rabbits 
were sacrificed and the small intestine from the pyloric sphincter to ileo-caecal 
junction was dissected. The mesentery was separated from the intestine. Then, 
the intestine was placed in 200ml of ice-cold 154mM KCl and processed within 
one hour. The remaining mesentery and fat were removed and the contents of the 
intestine were gently squeezed out. The small intestine was cleaned in 200ml of 
fresh ice-cold 154mM KCl solution. The small intestine was then cut 
longitudinally and washed thoroughly. Then, the intestine was blotted dry 
between tissue papers. The small intestine was weighed and then snap-frozen in a 
plastic bag in liquid nitrogen. The frozen small intestine was stored at -80°C. 
BBMV was prepared within one week after the dissection of small 
intestine. The frozen small intestine was thawed in 200ml of Buffer 1 and was cut 
into small pieces. The intestine fragments were mechanically vibrated for 1 
minute by a Vibro-mixer. Solution was filtered under vacuum to remove 
connective tissues and muscles and the filtrate was made up to 300ml by Buffer 
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1. The solution was mixed with 0.61g of MgCl� by gentle stirring to precipitate 
the nuclei，mitochondria，basolateral membranes and other cell debris. Then the 
solution was centrifuged at 4 � C , 3800 x g for 15 minutes. The supernatant was 
saved and centrifuged at 4°C，43000 x g for 30 minutes. The supernatant was 
discarded and the pellet was re-suspended in around 5ml of Buffer 2. The 
solution was centrifuged at 4°C，43000 x g for 40 minutes. The supernatant was 
discarded and the pallet was re-suspended in 1ml of Buffer 3. The pelleted 
volume was measured and the volume was doubled by the addition of Buffer 3. 
The solution was passed 5 times trough a 25 gauge needle to allow the formation 
of the BBMV. The solution was divided into 0.26ml aliquots and snap-frozen in 
liquid nitrogen. 
3.4.4.2 Preparation of the chloroform extract of the herbal water extract 
The chloroform extract of the water extract of the TCM herbal materials 
was used to perform the glucose uptake assay of BBMV because the trace 
amount of glucose in the herbal water extract interfere with the uptake reaction 
by the BBMV. The chloroform extraction was performed to remove the glucose 
content in the water extract. 
To obtain the chloroform extract of the water extract of the herbal 
materials，dried herbal aqueous extract was dissolved in distilled water at 
200mg/mL Equal volume of chloroform was added and mixed vigorously with 
the solution. The mixture was centrifuged at 1000 x g until a clear chloroform 
layer was separated from the water layer. The lower layer (chloroform) was 
collected with a pre-weighted glass tube. Extraction was repeated twice as 
described. The chloroform collections were-combined and the chloroform was 
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completely dried by nitrogen evaporator at 40�C. Weight of dried extract was 
recorded and the extraction yield was calculated. The chloroform extract was 
reconstituted to selected concentration by adding appropriate amount of distilled 
water with sonication. 
3.4.4.3 Glucose uptake assay of BBMV 
BBMV glucose uptake assay was performed based on the rapid 
filtration technique (Hopfer et al., 1973). D-glucose was used in the glucose 
uptake experiment instead of glucose analogs, e.g. 2-deoxy-D-glucose, because 
the BBMV do not contain glycolytic enzymes inside the vesicles. Therefore, the 
D-glucose transported into the vesicles would not be metabolized. 
Before making use of each batch of prepared BBMV, a time profile 
glucose uptake assay was carried out as a quality control experiment. One aliquot 
(0.26ml) of frozen BBMV was re-suspended in 0.44ml of Buffer 3. To start the 
reaction, 20^1 of BBMV was mixed with 40|LI1 of radioactive glucose solution 
containing O.lmM of D-glucose, lOOmM of sodium thiocyanate (NaSCN), 
lOOmM of mannitol, lOmM of HEPES-Tris，pH 7.4, lOjuCi/ml of D-[2-
Hjglucose. The reaction was performed at room temperature. In order to obtain 
the time profile of glucose uptake into BBMV, glucose uptake was stopped after 
certain incubation times (0，10, 20, 40，60，120, 300, 3600 seconds) by addition 
of 1ml of ice-cold stop-wash buffer to the incubated mixture, followed by rapid 
filtration through a pre-wetted 0.45jum nitrocellulose filter (Millipore, Billerica， 
m a , USA). The filter was washed 5 times with 1ml of ice-cold stop-wash buffer. 
The filters, which retained the BBMV, were each placed in a scintillation vial 
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together with 3.5ml of OptiPhase HiSafe 2 scintillation fluid. Radioactivity in 
aliquots was determined by a Packard Tri-Carb® 2900TR liquid scintillation 
counter (PerkinElmer Life Science Inc，Boston, MA, USA). The amount of 
radioactive glucose influx was normalized by the vesicles protein concentration, 
which was determined by BCA protein assay described in section 4.4.5. The 
batch of BBMV was functional if the glucose uptake increases sharply with time 
to a peak at around 10-40 seconds, followed by a gentle decrease of the 
radioactivity to 3600 seconds. 
To screen the effects of the herbal extracts, the glucose uptake of 
BBMV at fixed time point was performed. One aliquot (0.26ml) of frozen 
BBMV was re-suspended in 0.44ml of Buffer 3. BBMV (20JLI1) were mixed with 
30)^1 of the prepared herbal extract solution at appropriate concentration and lOjiil 
of radioactive glucose solution (40fxCi/ml of D-[2-^H]-glucose, 0.4mM of 
glucose, 400mM of NaSCN，400mM of mannitol, 40mM of HEPES-Tris, pH 
7.4). The reaction was performed at room temperature. The glucose uptake 
reaction was allowed to proceed for 20 seconds (the peak of the glucose uptake). 
The reaction was stopped and the BBMV was washed as mentioned above. The 
filters, which retained the BBMV, were subjected to radioactivity counting. The 
amount of radioactive glucose influx was normalized by the vesicles protein 
concentration, which was determined by BCA protein assay. 
In each experiment, a control and a ‘‘non-specific binding" reaction 
were performed. The control experiment was carried out by incubating the 
BBMV with distilled water instead of the herbal extract solution. It indicated the 
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normal glucose uptake reaction without the influence of the herbal extract. The 
"non-specific binding" reaction was performed under the same condition as the 
control experiment but ice-cold stop-wash buffer was added prior to the addition 
of radioactive glucose in order to determine the non-specific binding of the 
radioactive glucose on the BBMV surface membrane. 
Glucose uptake was expressed as amount of glucose uptake (pmol) per 
milligram of protein. The value of non-specific binding was subtracted from all 
samples for the correction of non-specific binding. To compare the effect of the 
herbal extract on the glucose absorption, the glucose uptake of the treatment 
group was expressed as percentage control. 
3.4.5 BCA (Bicinchoninic acid) protein assay 
BCA protein assay was performed by following previous protocol (Smith 
et al, 1985). Briefly, prior to the assay, the assay reagent was freshly prepared by 
mixing the assay bicinchoninic acid and copper (II) sulphate pentahydrate 
solution in a ratio of 50:1. . Then, 30^il of each BSA (bovine serum albumin) 
standard (0-1.25 mg/ml) and 30fAl of sample solution were added to 200f_il of the 
assay reagent in 96-well plate wells. Then, the plates were incubated at 37�C for 
30 minutes and cooled to room temperature after incubation. The absorbance was 
measured at 540nm by the Bio-rad model 3550 microplate reader (Bio-rad, 
Herculus, CA, USA). The protein concentration of the sample was calculated by 
the standard curve obtained from the BSA standard. 
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3.4.6 Statistical analysis 
For the statistical analysis，data were entered into and analyzed by using 
SPSS for Windows (version 11.5, SPSS Inc, Chicago, IL, USA). Mann-Whitney 
tests were used for the comparisons in all experiments between control and each 
herbal extract treated group，including the glucose uptake in 3T3-L1 adipocytes 
and Hs68 fibroblasts, the glucose production in H4IIE hepatoma cells and the 




3.5.1. Glucose uptake assay in 3T3-L1 adipocytes and Hs68 
fibroblasts 
To confirm the differentiation efficiency of 3T3-L1 adipocytes, the 
differentiated 3T3-L1 adipocytes were stained by oil red O (Figure 3.3). Oil red 
O can stain the neutral lipid in red. Cells without chemical induction showed no 
differentiation into adipocytes and no lipid accumulation. The cells remained 
typical spindle-shaped 3T3-L1 fibroblast morphology (Figure 3.3A). Cells with 
chemical induction showed lipid droplets accumulation and showed typical 
round-shaped 3T3-L1 adipocytes morphology (Figure 3.3B). 
Before screening the effects of the herbal extracts, a set of glucose uptake 
control experiment was carried out in the Hs68 fibroblasts. The time profile of 
the glucose uptake was obtained to ensure that the time selected (15 minutes) for 
radioactive 2-DG uptake was within the linear range of the uptake reaction The 
results showed that the glucose uptake was linearly increasing with time within 
30 minutes (Figure 3.4).，which proved that the time selected was appropriate for 
the screening process. The glucose uptake condition of 3T3-L1 adipocytes was 
referred to previously established information (Jarvill-Taylor et al., 2001). 
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Figure 3.3. Oil red O staining of 3T3-L1 cells (A) before chemical induction 
and (B) after chemical induction. Cells were fixed with 2% paraformaldehyde and 
oil red O working solution was added. The cells were allowed to stand at room 
temperature for lO-lSmin and then washed extensively with PBS. The stained cells 
were observed under light microscope. 
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Figure 3.4. The time profile of glucose uptake in Hs68 fibroblasts. Cells were 
glucose-starved for an hour, followed by the incubation in DMEM containing 
2|iCi/ml of 2-deoxy-D-[l-^H]glucose and O.lmM of 2-deoxy-D-glucose. The uptake 
reaction was stopped at different time points by the addition of ice-cold lOmM of 2-
DG solution. The amount of radioactive glucose influx was normalized by cell 
protein concentration. Data are expressed as mean 土 SEM (n = 6). 
>» 
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Formula 1 stimulated glucose uptake of 3T3-L1 and the uptake activity 
reached its maximum at Img/ml extract concentration, increasing the uptake by 
64% (p<0.05) over the control (Figure 3.5A). Similarly, formula 1 also 
stimulated glucose uptake in Hs68 fibroblasts (Figure 3.5B). The glucose uptake 
was increased by about 40%-60% (p<0.05). 
The 6 component herbs in formula 1，including Radix Astragali (黃耆)， 
Radix Rehmanniae (生地)，Rhizoma Smilacis Chinensis (炭葜)，Rhizoma 
Atractylodis Macrocephalae (白 jft), Radix Polygoni Multiflori Preparata (帝[j首 
烏）and Radix Stephaniae Tetrandra (漢防己)，were also tested for their effects 
on the glucose uptake in 3T3-L1 adipocytes and Hs68 fibroblasts (Figure 3.6). 
Although Radix Astragali and Radix Rehmanniae showed stimulation in 
glucose uptake in both cell lines, the trends in the two types of cells were 
different. In 3T3-L1 adipocytes, Radix Astragali increased the glucose uptake at 
lower dosage, giving a maximum of 83% of stimulation at O.lmg/ml (p<0.05), 
but showed inhibition at lOmg/ml. In Hs68 fibroblasts, this herb gave a different 
trend, showing a dose-dependent increase in the uptake and reaching maximum 
by increasing the uptake by 40% (p<0.05). Radix Rehmanniae exhibited a 58%-
68% of stimulation at lower dosage (O.Olmg/ml and O.lmg/ml) in 3T3-L1 
adipocytes. However, it did not show modulatory effect on glucose uptake at 
high concentration (Img/ml and lOmg/ml). Radix Rehmanniae also exerted a 
dose-dependent stimulation effect on the Hs68 fibroblast glucose uptake and the 
uptake reached the maximum at lOmg/ml by increasing the uptake by 31%. 
� 
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Rhizoma Atractylodis Macrocephalae showed stimulation in glucose 
uptake in 3T3-L1 adipocytes in lower dosage range (O.Olmg/ml-lmg/ml), giving 
a maximum of 43% increase at O.lmg/ml (p<0.05). However, it only gave minor 
stimulatory effect by 26.6% on the glucose uptake in the Hs68 fibroblasts at 
O.Olmg/ml (p<0.05). 
Radix Polygoni Multiflori Preparata and Rhizoma Smilacis Chinensis 
stimulated glucose uptake in both cell lines at lower dosage while inhibition was 
observed at higher dosage. For Radix Polygoni Multiflori Preparata, the 
stimulation in 3T3-L1 adipocytes reached its maximum at O.Olmg/ml by 
increasing the uptake by 55% (p<0.05) while such stimulation was observed in 
Hs68 fibroblasts at Img/ml by increasing the uptake by 43% (p<0.05). Inhibition 
was observed at lOmg/ml in both cell lines. For Rhizoma Smilacis Chinensis, 
83% of stimulation of glucose uptake in 3T3-L1 adipocytes was observed at 
O.lmg/ml (p<0.05) while such maximal stimulation was observed in Hs68 
fibroblasts at O.Olmg/ml by increasing the uptake by 43% (p<0.05). Inhibition 
was observed at lOmg/ml in both cell lines, which complete inhibition on the 
glucose uptake was observed in Hs68 fibroblasts. 
The effect of Radix Stephaniae Tetrandra was screened over a lower 
concentration range than the other herbs, from 0.1fj.g/ml to lOOjug/ml, because it 
showed cell death at higher dosages (Img/ml and lOmg/ml) (Data not shown). It 
showed no stimulatory effect on the glucose uptake in either cell lines，but an 
inhibitory effect of 37% to 54% on glucose uptake was observed in Hs68 
fibroblasts (p<0.05). 
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Figure 3.5. Effects of formula 1 on 2-DG uptake in (A) 3T3-L1 adipocytes and 
(B) Hs68 fibroblasts. 3T3-L1 adipocytes and Hs68 fibroblasts were incubated for 
30min without treatment, or with formula 1, or with insulin (lOOnM, in 3T3-L1 only, 
serves positive control), followed by the addition of 2-deoxy-D-[^H]glucose for 
glucose uptake assay. The uptake reaction was stopped at 15min incubation by the 
addition of ice-cold lOmM of 2-DG solution. The amount of radioactive glucose 
influx was normalized by cell protein. The glucose uptake values of the herbal 
extract treated group were expressed as the percentage of the untreated control group. 
Data are expressed as mean + SEM (n = 30). * Significant difference between 
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Figure 3.6. Effects of component herbs of formula 1 on 2-DG uptake in (A) 
3T3-L1 adipocytes and (B) Hs68 fibroblasts. 3T3-L1 adipocytes and Hs68 
fibroblasts were incubated for 30min, with or without herbal extract treatment, or 
with insulin (lOOnM, in 3T3-L1 only, positive control (see inset)), followed by the 
addition of 2-deoxy-D-['H]glucose for glucose uptake assay. The uptake reaction 
was stopped at 15min incubation by the addition of ice-cold lOmM of 2-DG solution. 
The amount of radioactive glucose influx was normalized by cell protein. The 
glucose uptake values of the herbal extract treated group were expressed as the 
percentage of the untreated control group. Data are expressed as mean + SEM (n 二 
18 - 24). * Significant difference between untreated control and herbal extract or 
insulin treated groups (p < 0.05). 
3.5.2. Glucose production and PEPCK assay in H4IIE hepatoma 
cells 
Formula 1 and its components were tested for their effects on 
gluconeogenesis in the H4IIE hepatoma cells using glucose production assay. 
The limitation of this assay is that a large sample size could not be handled at the 
same time. Therefore, the test was only repeated for 3 times at each condition 
with sample size equaling to 1 in each experiment. It was considered undesirable 
to perform statistical analysis with such a small sample size. Hence，those herbs 
with comparable effects to insulin treatment (positive control) on inhibition of 
glucose production were regarded as active herbs. Only the results of these active 
herbs are presented in Figure 3.7. The results of the other herbs were not 
promising and their results are shown in Table 3.1. The glucose production assay 
of Radix Stephaniae Tetrandra at 5mg/ml was not performed because 
cytotoxicity was observed at this dosage. 
From the glucose production assay, only Rhizoma Smilacis Chinensis 傻 
葜）and Radix Polygoni Multiflori Preparata (制首烏）showed comparable 
inhibitory effect to insulin at high herbal extract dosages (Figure 3.7). Insulin 
treatment (lOnM) showed 74% of inhibition in the glucose production assay. The 
glucose production in Rhizoma Smilacis Chinensis treatment group was inhibited 
by 77.6% and 81.9% at 1 mg/ml and 5mg/ml respectively. Radix Polygoni 
Multiflori Preparata only showed 76.7% of inhibition at 5mg/ml when compared 
to the untreated group (negative control). However, it showed slight activation of 
27.3% at Img/ml. Lower dosages of these two herbs did not showed remarkable 
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Figure 3.7. Effects of Rhizoma Smilacis Chinensis and Radix Polygoni 
Multiflori Preparata treatment on glucose production in H4IIE hepatoma cells. 
Cells were incubated with DEX/pCPT-cAMP, without additional treatment, or with 
herbal extracts, or with lOnM of insulin, then glucose production buffer containing 
gluconeogenic precursors was added, followed by determination of glucose released 
into the glucose production buffer by enzymatic-spectrophotometric glucose 
oxidase/peroxidase assay. The amount of glucose produced was normalized by cell 
protein. The glucose production values of the herbal extract treated group were 
expressed as the percentage of the untreated control group. Data are expressed as 
mean + SEM (n = 3). 
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Percentage stimulation or inhibition of glucose 
production (compared to negative control) 
Herbal extract concentration (mg/ml) Herbal extracts 
0.04 0.2 1 5 
Formula 1 +2.5% +4.3% +5.5% +18.7% 
Radix Astragali (黃耆） -9.5% +76.5% +115.6% +23.8% 
Radix Rehmanniae (生地） +46.4% +172.2% +32.9% +45.5% 
Rhizoma Atractylodis Macrocephalae _ 
(白求） ^ -8.5% -26.2% -17.1% -10.0% 
Radix Stephaniae Tetrandra (漢防己） -1.7% +5.7% +1.3% — 
Table 3.1. Summary of the effects of the formula 1 and its component herbs 
(except Rhizoma Smilacis Chinensis and Radix Polygoni Multiflori Preparata) 
on glucose production in H4IIE hepatoma cells. The glucose production values of 
the herbal extract treated group were expressed as the percentage of the untreated 
control group. The percentage values represent the extent of stimulation or inhibition 
of glucose production at each concentration (n = 3). The glucose production assay of 
Radix Stephaniae Tetrandra at 5mg/ml was not performed because cytotoxicity was 
observed at this dosage. 
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To further confirm the effect of the herbs on gluconeogenesis and 
elucidate the possible mechanism of the herbal action on glucose production, 
PEPCK activity assay was performed. This time, with larger sample size, 
statistical analysis was performed. The result of the PEPCK assay is shown in 
Figure 3.8. Insulin treatment (lOnM) showed 58% inhibition of PEPCK activity 
(p<0.05). Similar to the results of the glucose production assay, Rhizoma 
Smilacis Chinensis and Radix Polygoni Multiflori Preparata significantly 
inhibited the PEPCK activity only at 5mg/ml by 52.0% and 42.6% respectively 
(p<0.05). Interestingly, Rhizoma Smilacis Chinensis did not show significant 
decrease in PEPCK activity at Img/ml; however, about 80% of inhibition on 
glucose production was observed at this dosage. Consistent with the glucose 
production assay result, Radix Polygoni Multiflori Preparata showed mild 
activation (33.0%, p<0.05) on the PEPCK activity at Img/ml and both herbs 
showed no effect on PEPCK activity at lower dosages. 
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Figure 3.8. Effects of Rhizoma Smilacis Chinensis and Radix Polygoni 
二了職ri Preparata treatment on PEPCK activity in H4IIE hepatoma ce„s. 
Cells were incubated with DEX/pCPT-cAMP, without additional treatment, or with 
herbal extracts，or with lOnM of 卿Hn�Cel l s were then lysed and the lysate was 
m ^ d with PEPCK assay buffer containing NADH to measure the PEPCK activity by 
the rate of NADH consumption using spectrophotometric method. The PEPCK 
activity was normalized by cell protein. The PEPCK activities of the herbal extract 
treated group were expressed as the percentage of the untreated control group Data 
are expressed as mean + SEM 二 8 _ 9). * Significant difference between untreated 
control and herbal extract or insulin treated groups (p < 0.05). 
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3.5.3. Glucose uptake assay in BBMV 
Chloroform extraction on the herbal water extracts was performed prior to 
the BBMV glucose uptake assay. From the result shown in Table 3.2，the yield of 
extraction was low (0.2% to 0.7%) in most of the herbs, except Radix Stephaniae 
Tetrandra (漢防己)，which had the percentage yield of 3.2%. The chloroform 
extraction was carried out to remove the glucose content in the water extract 
because the trace amount of glucose in the herbal water extract would affect the 
uptake reaction by the BBMV. However, chloroform extraction would also lead 
to the loss of the polar compounds from the herbal extracts. 
Since a number of batches of BBMV were prepared, to confirm the 
functionality of each batch of BBMV, a quality control experiment on the glucose 
uptake time profile was performed. Show in Figure 3.9，a typical bell-shaped 
curve on the glucose uptake profile was obtained, showing that the glucose 
uptake of BBMV achieved maximum at 20 seconds and after that, the glucose 
trapped in the BBMV gradually decreased (Kessler et al., 1978; Semenza et al, 
1984). The transient overshoot of the glucose influx at the initial reaction was due 
to the sodium ion gradient across the brush border membrane. As the sodium 
gradient faded out, the glucose concentration inside and outside the BBMV 
gradually attained equilibrium (3600 seconds). Only the batches of BBMV with 
the bell-shaped glucose uptake profile similar to Figure 3.9 were used for the 
subsequent experiments. 
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Equivalent aqueous extract 
Herbs Yield concentration (mg/ml) to Img/ml 
of chloroform extract 
Formula 1 0.5% 200 
Radix Astragali (黃耆） 0.2% 500 
Radix Rehmanniae (生地） o.2% 500 
Rhizoma Smilacis Chinensis (蔬葜） 0.3% 333.33 
Rhizoma Atractylodis Macrocephalae (白7ft) 0.7% 142.86 
Radix Polygoni Multiflori Preparata (帘[I首烏） 0.3% 333.33 
Radix Stephaniae Tetrandra (漢防己） 3.2% 31.25 
Table 3.2. The percentage yield of the chloroform extraction from the herbal 
aqueous extract and the equivalent aqueous extract concentration to Img/ml of 
chloroform extract. The extraction yield was calculated by the ratio of the weight of 
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Figure 3.9. The glucose uptake profile of BBMV. BBMV were mixed with ^H-
glucose at room temperature and the glucose uptake reaction was stopped at different 
times by the addition of stop-wash buffer. The amount of radioactive glucose influx 
was normalized by the vesicles protein concentration. Data are expressed as mean 土 
SEM (n = 11 - 12). 
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To effectively inhibit glucose absorption from the intestine, the substance 
should be able to inhibit the absorption during the maximal glucose uptake, i.e. 
at 20 seconds. Glucose transport across the brush border membrane is primarily 
unidirectional up to this time point. Moreover, detecting the inhibition at the 
maximum point can increase the sensitivity of the detection of the inhibitory 
effect. Therefore, in the subsequent experiments, the drugs were screened for 
their inhibitory effects on BBMV glucose uptake at 20 seconds of reaction. 
From the herbal extract experiments (Figure 3.10)，four out of the seven 
herbs tested showed significant inhibitory effect on glucose absorption at the 
dosage of Img/ml chloroform extract. The four effective extracts included 
Formula 1, Radix Astragali (黃耆)，Rhizoma Atractylodis Macrocephalae (白 jft) 
and Radix Stephaniae Tetrandra and they showed 42.3%, 35.4%, 66.3% and 
44.1% of inhibition, respectively (p<0.05). 
Interestingly, when the dosage effects of formula 1, Radix Astragali and 
Rhizoma Atractylodis Macrocephalae were tested, all the herbal chloroform 
extracts showed dose-dependent inhibition on the glucose uptake (Figure 3.11). 
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Figure 3.10. Effects of the chloroform extracts of the herbal water extracts on 
glucose uptake of BBMV. BBMV were mixed with ^H-glucose, without additional 
treatment, or with herbal chloroform extracts (Img/ml), at room temperature and the 
glucose uptake reaction was stopped at 20sec by the addition of stop-wash buffer. 
The amount of radioactive glucose influx was normalized by the vesicle protein 
concentration. Data are expressed as mean + SEM (n = 11 - 12). * Significant 
difference between untreated control and herbal extract treated groups (p < 0.05). 
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Figure 3.11. The dose-dependent inhibition of BBMV glucose uptake by formula 
1，Radix Astragali and Rhizoma Atractyiodis Macrocephalae. BBMV were 
mixed with H-glucose, without additional treatment, or with herbal chloroform 
extracts, at room temperature and the glucose uptake reaction was stopped at 20sec 
by the addition of stop-wash buffer. The amount of radioactive glucose influx was 
normalized by the vesicles protein concentration. Data are expressed as mean 土 SEM 
(n = 8 - 9). * Significant difference between untreated control and herbal extract 
treated groups (p < 0.05). 
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3.6. Discussion 
3.6.1. Glucose uptake in 3T3-L1 adipocytes and Hs68 fibroblasts 
All herbal water extracts except Radix Stephaniae Tetrandra (漢防己） 
demonstrated stimulatory effects on glucose uptake in 3T3-L1 adipocytes and 
Hs68 skin fibroblasts. These observations imply the possibilities that the 
effective herbal extracts may also promote glucose uptake in vivo and improve 
glucose clearance from the bloodstream. The stimulatory effect of Radix 
Rehmanniae (生地）in Hs68 fibroblasts was in a dose-dependent manner. Other 
herbs such as Rhizoma Smilacis Chinensis 葜)and Radix Polygoni Multiflori 
Preparata (芾[]首烏）stimulated glucose uptake in lower dosages but inhibited 
glucose uptake at high dosage (lOmg/ml). These observations indicate that these 
herbal extracts are effective at different dose ranges. In addition, the effects of 
the herbal extracts were different in the two cell lines. For example，Radix 
Astragali (黃耆)stimulates glucose uptake in Hs68 fibroblasts at lOmg/ml but 
inhibits the uptake in 3T3-L1 adipocytes at this concentration. This implies that 
the effects of the herbal extracts were also tissue-specific. 
A wide range of compounds were shown to have stimulatory effect on 
3T3-L1 adipocytes glucose uptake, for example, arachidonic acid (Nugent et al., 
2001) and endothelin (Wu-Wong et al., 1999). Thiazolidinediones have been 
targeted to the adipose tissue to increase the glucose uptake and decrease the 
insulin resistance in diabetic patients (Arner, 2003). Traditional Chinese herbal 
medicines, such as Radix Ginseng and Radix Asparagi, also possess similar 
activities (Hong et al, 2000). The herbal extracts which demonstrated 
stimulatory effect on the glucose uptake in the 3T3-L1 adipocytes in this study 
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could potentially improve glucose transport in the adipose tissue in vivo. 
However, further experiments are needed to such this effect. 
Although skin fibroblast is not a major insulin responsive tissue, it is 
believed that the stimulation in the basal glucose uptake in insulin non-
responsive tissues can also enhance the glucose clearance from the bloodstream 
(Gherzi et al., 1992). Moreover, the glucose uptake into fibroblasts may give 
insight to the therapeutic effects of these herbal extracts on diabetic foot ulcer. 
One of my colleagues is working on the effects of these herbal extracts on cell 
proliferation. Preliminary results showed that Radix Astragali, Radix 
Rehmanniae (生地）and Rhizoma Atractylodis Macrocephalae (白 jft) stimulated 
proliferation of skin fibroblast cell line. Moreover，the dosages which showed 
positive results in the glucose uptake experiment and the proliferation 
experiment are approximately the same. However, not all herbal extracts that 
stimulated glucose uptake could promote cell proliferation. This indicates that 
glucose uptake is not the sole factor affecting the cell proliferation (Lau et al., 
unpublished data). 
The effects of the herbs on glucose transport observed in the two cell 
types were probably mediated by glucose transporters. In the 3T3-L1 adipocytes, 
Glutl and Glut4 are expressed. The herbal extracts may possess insulin-like 
effects on the 3T3-L1 adipocytes and stimulate the translocation of the Glut4 
proteins from the intracellular vesicles to the plasma membrane (Harrison et al., 
1992). Translocation of Glutl may also occur, but the extent of translocation is 
much less than that of Glut4 (Calderhead et al., 1990). The stimulation in 
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glucose uptake observed in Hs68 fibroblast was most likely mediated by the 
activation of Glutl and Glut3 proteins on the plasma membrane (Longo et al.， 
1992). However, the stimulation observed in glucose uptake in both cell lines 
was likely not mediated by the translational activation of glucose transporters. It 
is because the cells were incubated with the herbal extracts for 30 minutes, but 
the translational activation of glucose transporters usually takes more than 2 
hours (McGowan et al., 1995). Nevertheless, further experiments are required to 
confirm the involvement of different glucose transporters in mediating the 
effects of different herbs. 
Radix Stephaniae Tetrandra was cytotoxic to the 3T3-L1 adipocytes and 
Hs68 fibroblasts at Img/ml and lOmg/ml (Data not shown). No toxicity of this 
herb was previously reported. Moreover, a number of herbal extracts tested 
showed inhibitory effect on the glucose uptake at higher concentrations. The 
inhibition of glucose uptake may be caused by the disruption of pH of the 
extracellular environment during the herbal extract incubation. At the dosage 
that glucose uptake was inhibited, there was no obvious cell death observed. 
Further experiments are needed to confirm the cytotoxicity of these herbs. Apart 
from the cytotoxicity，the glucose present in the herbal extracts may also be 
responsible for the inhibition of the glucose uptake at higher herbal extract 
concentrations. However, since the cells were washed extensively after herbal 
extract incubation and before radioactive glucose incubation, the glucose present 
in the herbal extracts should not directly compete with the radioactive glucose 
for the glucose transporters. Furthermore，such inhibition was not exclusively 
observed in herbal extracts with high glucose content. For example, the glucose 
content of Radix Astragali extract was lower than Radix Rehmanniae, but 
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glucose uptake inhibition was only observed in Radix Astragali at lOmg/ml but 
not in Radix Rehmanniae in 3T3-L1 adipocytes. Therefore，the glucose content 
in the herbal extracts cannot fully explain the inhibition on glucose uptake 
observed at high herbal extract concentration. 
In the future, mechanistic study of the stimulation of glucose uptake in 
the two cell lines can be conducted. Stimulation of glucose uptake in adipocytes 
may be mediated by the translocation of Glut4 from intracellular vesicles to 
plasma membrane. To confirm this effect of the active herbal extracts, western 
blot analysis on the amount of Glut4 on the plasma membrane using subcellular 
fractionation can be conducted (Perrini et al., 2004). Alternatively, Glut4-GFP 
(green fluorescence protein) fusion construct can be employed to study the 
subcellular localization of Glut4 after herbal extract treatment (Powell et aL, 
1999). Moreover, the herb-insulin interaction can be studied by the insulin-
stimulated glucose uptake in the 3T3-L1 adipocytes to elucidate the interaction 
between insulin and the herbal, extracts (Kamei et al., 2002). For the stimulation 
of glucose uptake in Hs68 fibroblasts, since the incubation time of herbal 
extracts with cells was only 30 minutes, it is not likely that the extracts would 
increase the glucose uptake by activating translation level of Glutl. To confirm 
the effect of the herbal extracts on Glutl, protein synthesis inhibitors can be used 
(Khayat et aL, 1998). 
122 
3.6.2. Glucose production and PEPCK activity in H4IIE 
hepatoma cells 
Rhizoma Smilacis Chinensis (蔬葜）and Radix Polygoni Multiflori 
Preparata (制首烏）inhibited the glucose production, accompanied by the 
inhibition of the PEPCK activity in H4IIE cells. 
In the functional assay of PEPCK, both herbs showed about 50% of 
inhibition on the PEPCK activity at 5mg/ml, which is less than the extent of 
inhibition in glucose production assay. Moreover, the PEPCK activity was not 
inhibited by Img/ml of Rhizoma Smilacis Chinensis (蔬葜)while about 80% of 
inhibition on glucose production was observed at this dosage. The results 
indicated that these two herbs may also inhibit gluconeogenesis through other 
mechanisms, e.g. glucose-6-phosphatase (G6Pase) activity, since PEPCK and 
G6Pase are the two major controlling enzymes in the gluconeogenesis pathway 
(Lochhead et al., 2000). G6Pase is one main target in current diabetic 
medication (Davies et al., 1999). Therefore, the effects of the herbs on G6Pase 
activity deserve further investigation. 
The inhibitory effect of Rhizoma Smilacis Chinensis and Radix Polygoni 
Multiflori Preparata on glucose production was observed at 5mg/ml. It is 
difficult to justify that this high concentration of the herbal extract would be 
present in the human liver. It can only be speculated that the herbal extract 
concentration in the liver is higher than elsewhere in the body because the 
digestion products from the extracts firstly reach the liver after absorption from 
the intestine. For example, research found that the exposure of the liver to 
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metformin is about five times more than that in the systemic circulation 
(Stepensky et al., 2002). Inhibition of glucose production and PEPCK activity 
observed in high herbal extract concentration would raise another concern that 
the inhibition observed was the result of cytotoxicity, since it was found that 
cytotoxic chemicals would also decrease gluconeogenesis activity (Ashida et al., 
2000). However, no sign of cell death was observed after five hours of herbal 
extract incubation. 
Apart from metformin and some other pure compounds, a few herbs and 
their pure components have been shown to have inhibitory effect on the H4IIE 
glucose production. For example, epigallocatechin gallate, a constituent of green 
tea, has been shown to mimic the insulin effect by activating mitogen-activated 
protein kinase cascade and the phosphatidylinositol 3-kinase pathway. Both 
pathways lead to the suppression of PEPCK and G6Pase gene transcription 
(Barthel and Schmoll, 2003). 
The H4IIE cell line provides a simple model for the test on glucose 
production. However, in the present study, the interaction between herbs and 
hormones were not studied. Since many hormones are involved in maintaining 
hepatic glucose production in the body，the herb-hormone interaction may be 
studied in the future by co-incubating the hepatoma cells with hormones and 
herbal extracts. 
In summary, Rhizoma Smilacis Chinensis and Radix Polygoni Multiflori 
Preparata extracts inhibited glucose production as well as PEPCK activity in 
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H4IIE hepatoma cells. Such observations imply the possibilities that these herbal 
extracts may also inhibit hepatic glucose production in vivo. 
3.6.3. Glucose absorption in BBMV 
Formula 1， Radix Astragali (黃耆），Rhizoma Atractylodis 
Macrocephalae (白jft) and Radix Stephaniae Tetrandra (漢防己）inhibited Sgltl 
activity in the BBMV and except Radix Stephaniae Tetrandra, the inhibitory 
effects on the glucose uptake were dose-dependent. 
When the dosage of the chloroform extract is converted back to the 
equivalent aqueous extract by the percentage yield of chloroform extraction, the 
dosage is much higher than that used in other in vitro assays (Table 3.2). 
Alternatively, a bioequivalence study can be performed between crude herbal 
extracts and chloroform extracts so that the effective dosage of the herb could be 
determined. Radix Stephaniae Tetrandra (漢防己）is the most potent among the 
others since its effective dose is much lower than the other effective herbs. 
Chloroform extraction on the herbal water extracts were performed 
because it was found that the herbal extracts contained glucose from the HPLC 
analysis in section 2.5.3. The glucose content in the herbal water extracts would 
interfere with the glucose uptake of the BBMV and give false positive results. In 
the BBMV glucose uptake assay, BBMV was incubated with herbal extract 
together with radioactive glucose solution and the final glucose concentration in 
the reaction mixture was 0.067mM，or equivalent to 0.012mg/ml. The glucose 
content in the herbal water extract was comparable to that in the BBMV assay 
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solution. For example, Rhizoma Atractylodis Macrocephalae, which contained 
the least amount of glucose among all (0.66% w/w), the concentration of glucose 
in Img/ml herbal water extract solution would be 0.0066mg/ml, which is about 
half of the value of the glucose concentration in the BBMV assay. Therefore, it 
was necessary to remove the glucose from the water extracts. However, 
chloroform extraction inevitably causes the loss of polar substances which may 
also possess such inhibitory effect on the transporter. At present, there is no 
effective method to eradicate glucose without affecting the content of other 
chemicals from the extracts. 
The yield of chloroform extraction was generally very low. Except Radix 
Stephaniae Tetrandra, the percentage yields of the other herbal extract were less 
than 1%. It was because the starting materials of chloroform extraction were the 
water extract of the herbal materials. It indicates that most of the non-polar 
substances in the raw herbal materials were removed by the water extraction and 
most of the compounds in the water extracts were polar. 
The inhibition of these herbal extracts was possibly caused by direct 
interaction with the Sgltl protein (Klaren et al., 2000). Apart from the direct 
interaction, the change of the membrane fluidity of the vesicles was another 
possible mechanism for the inhibition (Proulx，1991). For future experiments, 
these herbal extracts can be tested for their effects on the Mg^^-ATPase which 
would affect the membrane fluidity (Kitagawa et al,, 1995). BBMV provides a 
simple model for rapid screening of the herbal extracts on the Sgltl. The vesicle 
contains no enzymes and ribosomes; therefore, it has no transcriptional and 
translational modification of the transporter： Any effect observed is likely to be 
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the direct interaction of the substance to the transporter. However, this model 
does not allow for the examination of the regulatory mechanisms on the 
transporters and other factors affecting the intestinal glucose uptake, e.g. the 
effect on a-glucosidase. 
In summary, the chloroform extracts of formula 1, Radix Astragali, 
Rhizoma Atractylodis Macrocephalae and Radix Stephaniae Tetrandra water 
extracts inhibited Sgltl activity in the apical membrane of rabbit small intestinal 
enterocytes shown by the BBMV model. These observations imply the 
possibilities that these herbal extracts may inhibit the intestinal glucose 
absorption and ameliorate postprandial hyperglycaemia in vivo. 
127 
3.6.4. Conclusion 
The in vitro studies attempted to simulate the individual tissues in the 
body which are targeted by current anti-diabetic medication. The glucose 
homeostasis regulation of these tissues by the herbal extracts may give 
implications on the regulation of the systemic glucose level in the body (Figure 
3.1). Table 3.3 summarizes the effects of the herbs in the in vitro models. In the 
Hs68 fibroblast and the 3T3-L1 adipocyte systems, increase in the glucose 
uptake was desirable while in the H4IIE hepatoma cells and the BBMV systems, 
decrease in the glucose production and absorption were the desirable effects, 
respectively. Increase in glucose uptake in 3T3-L1 adipocytes and Hs68 
fibroblasts indicate that the herbal extracts may enhance glucose clearance from 
the bloodstream (Szalkowski et al., 1995). Inhibition of the glucose production 
in H4IIE hepatoma cells indicates that the herbal extracts may reduce the 
glucose input into the bloodstream (Lochhead et al., 2001). Inhibition of BBMV 
glucose uptake implies the effects of the herbal extracts on inhibiting intestinal 
glucose absorption and ameliorating postprandial hyperglycaemia (Creutzfeldt 
and Folsch, 1983). 
Formula 1, Radix Astragali (黃耆)，Rhizoma Smilacis Chinensis (蔬葜)， 
Rhizoma Atractylodis Macrocephalae (白 j f t) and Radix Polygoni Multiflori 
Preparata ($[]首烏）showed positive results in at least three of our four in vitro 
screening systems. Rhizoma Smilacis Chinensis was the most powerful herb 
according to our in vitro screening systems. This herb was highly active in 
promoting glucose uptake in Hs68 fibroblasts and 3T3-L1 adipocytes and 
inhibiting glucose production in H4IIE hepatoma cells. Therefore, Rhizoma 
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Smilacis Chinensis was chosen for further investigation on its anti-diabetic 
effects in vivo. The effect of formula 1 was also studied in the in vivo system due 
to its relevance to the clinical study. In addition, formula 1 was also highly 
active in inhibiting glucose absorption in BBMV and stimulating glucose uptake 

















































































































































































































































































































































































































































































































Chapter 4: The anti-diabetic effects of formula 1 and 
Rhizoma Smilacis Chinensis in vivo 
4.1 Introduction 
Rhizoma Smilacis Chinensis, the herb which gave the most promising results in 
the in vitro screening systems, as well as formula 1，were further tested for their anti-
diabetic effects in an animal model. 
4.1.1 Diabetic animal models 
Diabetes mellitus is a multifactorial disorder characterized by 
hyperglycaemia. This project focuses on type 2 diabetes. Currently, there are a 
number of animal models of type 2 diabetes available; however, it must be noted 
that these models differ significantly from each other and none of them is 
equivalent to the human diabetes (Bell and Hye，1983). Therefore, the 
characteristics and the limits of each model should be recognized and the animal 
model should be chosen according to the research interests. 
Rats and mice are the most commonly used animal models for the 
diabetes study because they are easier to manipulate as compared to larger 
animals. Therefore, only the models using rats and mice are described. At present, 
two major types of diabetic rat and mice models are being used for investigation 
(Mcintosh and Pederson, 1999): 
(a) Genetically manipulated animals; 
(b) Chemically manipulated animals. 
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(a) Genetically manipulated rat and mice models 
From a number of epidemiological and twin studies, genetic 
predisposition of the individual is an important aetiological factor for type 2 
diabetes in human (Froguel and Hager，1995). Studies have revealed mutations in 
a number of candidate genes including those for insulin，insulin receptor, 
glucokinase and mitochondrial tRNA (Elbein，1997). The genetic rodent models 
of diabetes provide important insights into the aetiology of this disorder. Some 
genetic rodent models are monogenic, such as db/db mice (Dong et al” 1997) and 
Zucker diabetic fatty rat (Zawalich et al, 1995). Some of them are polygenic, 
such as the Japanese KK mice (Mcintosh and Pederson, 1999)，and the others are 
transgenic or knockout mice, such as IR/IRS-l+z— mice (Mauvais-Jarvis et al., 
2002). However，none of these models can adequately address the aetiologic and 
genetic conditions of diabetes. For example, ob/ob and db/db mice differ in many 
aspects from the typical diabetic patients and few patients exhibit the degree of 
obesity that characterizes these mice (Luo et al., 1998). 
(b) Chemically manipulated rat and mice models 
Common chemically manipulated rodent diabetic models make use of 
cytotoxic chemicals specific to pancreatic p-cells, such as alloxan and 
streptozotocin (STZ), to induce diabetes. The damages in the endocrine pancreas 
would create a deficiency or a complete loss of insulin secretion, depending on 
the time of chemical induction (Rodrigues et al., 1999). Diabetes can be induced 
by neonatal injection of alloxan or streptozotocin into rats (Kodama et al., 1993)， 
developing an insulin-deficient state and creating a mild and stable 
hyperglycaemic condition in the rats (Portha et al., 1979). Insulin resistance is 
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also found in these chemically induced diabetic animals. The co-existence of 
insulin resistance and impaired insulin action endows this neonatally chemically 
induced rats a model of diabetes (Blondel et al.’ 1989). 
4.1.2 Neonatal streptozotocin-induced diabetic rat model 
In this project, neonatal streptozotocin-induced diabetic rat model was 
used as the animal model for the study of the anti-diabetic effects of the herbal 
extracts. This model was first described by Portha et al (1974) and the diabetic 
condition was created by a single dose of streptozotocin via intravenous (i.v.) 
injection. Since then, the induction method has been modified and now, the 
regime of a single dose of intraperitoneal (i.p.) injection of STZ into neonatal rats 
is commonly used (Rodrigues et aL, 1999). 
STZ is a cytotoxic chemical specific to pancreatic p-cells isolated from 
Streptomyces achromogenes. Structurally, streptozotocin contains a glucose-like 
moiety (Figure 4.1) that enables it to be selectively taken up by the pancreatic 
p-cells via glucose transporter type 2 (Glut2) (Schnedl et al., 1994) and causing 
cell death after its entry. Although the exact mechanism of cell death is still 
unknown, it is believed that the nitrosurea group of STZ can cause alkylation of 
DNA (Delaney et aL, 1995) and act as a nitric oxide donor. The nitric oxide 
produced when streptozotocin is metabolized in the p-cells causes DNA damage 
directly or via reactive oxygen species (Kroncke et aL, 1995). The reactive 
oxygen species can also trigger a number of disastrous consequences and lead to 
cell death (Takasu et aL, 1991). For example, they would cause inhibition of the 
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electron transport chain (Turk et al., 1993) as well as ATP and NAD+ depletion 
in the (3-cells (Nukatsuka et aL, 1990). 
HCX� 1 H z1 O�� H rt � . -^ H Iji > 
OH 1 f OH � 
\ f � : H 3 . 
6 
Figure 4.1. The chemical structure of streptozotocin. Streptozotocin contains a 
nitrosurea group linked to a glucose moiety that allows its entry into the pancreatic p-
cells via Glut2. 
Diabetes is created by the pancreatic P-cells damage caused by STZ in the 
neonates, followed by limited p-cells regeneration. At 6 to 22 weeks of age, 
persistent hyperglycaemia and impaired insulin secretion are found in the animals 
(Bonner-Weir et al” 1981). Several regimes with different time and dosage of 
STZ injection have been developed. In this part of the project, two types of 
neonatal STZ-induced diabetic rat models were used, namely nO-STZ and n5-
STZ. The nO-STZ model was created by introducing STZ (lOOmg/kg body 
weight) i.p. injection within 1 day after birth while the n5-STZ model was made 
by introducing the STZ (70mg/kg body weight) i.p. injection 5 days after birth. 
Owing to the pancreatic p-cells destruction by STZ, these diabetic rats are 
marked by a decreased insulin stores and hence, hyperglycaemia and glucose 
intolerance (Weir et al., 1981). However, the severity of the diabetic condition in 
these two models is quite different. Since the regeneration activity of the 
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pancreatic P-cells deteriorates with age, nO-STZ rats can regenerate more p-cells 
than n5-STZ rats and the diabetic condition of n5-STZ rats is more severe than 
that of the nO-STZ rats (Mcintosh and Pederson, 1999). The pancreatic insulin 
content of the n5-STZ is 90% depleted at the age of 10 weeks while that of the 
nO-STZ is only 50% depleted at the same age (Blondel et al” 1989). Therefore， 
the nO-STZ rats show only mild hyperglycaemia while the n5-STZ rats show 
more severe hyperglycaemia. However, insulin resistance is only found in n5-
STZ rats but not in the nO-STZ rats (Blondel et al., 1989; Kergoat and Portha， 
1985). 
The STZ-induced diabetic rat model was used in the study of the anti-
diabetic effects of formula 1 and Rhizoma Smilacis Chinensis (蔬葜).Formula 1 
and Rhizoma Smilacis Chinensis were tested for their anti-diabetic effects in the 
nO-STZ and n5-STZ rat models by two tests, oral glucose tolerance test and basal 
glycaemia test. Oral glucose tolerance test monitors the anti-hyperglycaemic 
effect of the herbs after introducing herbal extract treatment followed by glucose 
challenge. Basal glycaemia test monitors the basal fasting plasma glucose 
following the herbal extract treatment to a fasting rat. 
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4.2 Objective 
The objective of this part of the project is to evaluate the anti-hyperglycaemic 
/ 
and hypoglycaemic effects of formula 1 and Rhizoma Smilacis Chinensis on the oral 





Neonatal female albino Wistar rats were supplied by and kept at The 
Laboratory Animal Services Centre, The Chinese University of Hong Kong. 
Three to four rats were kept in a wire-bottomed cage and acclimated under the 
conditions of 22-25°C and a 12-hour light-dark cycle. The animals were supplied 
with standard rodent diet, Prolab 2500 rodent diet, and allowed free access to tap 
water. The animal study was approved by Animal Experimentation Ethics 
Committee under the project license number 02/022/MIS. 
4.3.2 Chemicals and reagent kit 
All chemicals were purchased from Sigma，St. Louis，MO, USA. 
a) Streptozotocin (STZ) 
Streptozotocin was dissolved in citrate buffer (0.028M of citric acid 
monohydrate and 0.255M of citric acid trisodium salt dehydrate, pH4.5) to the 
concentration of 20mg/mL The STZ solution was freshly prepared before use. 
b) Heparin sodium salt from porcine intestinal mucosa 
Heparin was dissolved in distilled water to the concentration of 
1250U/ml. 
c) Glucose 
Glucose was dissolved in distilled water to 400mg/ml for the oral glucose 
tolerance test. Brief sonication was performed to ensure complete dissolution. 
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d) Metformin 
Metformin was dissolved in distilled water to the concentration of 
200mg/ml for the oral glucose tolerance test and the basal glycaemia test. 
e) Enzymatic-spectrophotometric glucose oxidase/peroxidase assay kit 
Enzymatic-spectrophotometric glucose oxidase/peroxidase assay kit was 
purchased from Biosystems S.A.，Spain. The assay kit includes a bottle of assay 
reagent, containing 70mmol/L of phosphate, 5mmol/L of phenol, more than 
lOU/ml of glucose oxidase, more than lU/ml of peroxidase, 0.4mmol/L of 4-
aminoantipyrine, at pH 7.5, and a bottle of glucose/urea/creatinine standard, 




4.4.1 Induction of diabetes in rats 
The nO-STZ diabetic rats were induced according to protocol previously 
described by Barbara et al (1997). Freshly-prepared STZ solution (20mg/ml) was 
injected into one-day old female Wistar rats intraperitoneally (lOOmg/kg body 
weight) for the use in oral glucose tolerance test. The n5-STZ diabetic rats were 
induced according to previously described protocol (Gokhale et al” 1998). 
Freshly-prepared streptozotocin solution (20mg/ml) was injected into five-day 
old female Wistar rats intraperitoneally (70mg/kg body weight) for the use in 
basal glycaemia test. At week 4 or 5，the rats were separated from their mothers. 
The rats were used for experiment at the age of week 10-12. 
4.4.2 Oral glucose tolerance test 
The nO-STZ diabetic rats at the age of week 10 to 12 were used in the oral 
glucose tolerance test. The diabetic condition was confirmed by the 
determination of fasting hyperglycaemia at 7.0mM or over in the adult rats. The 
herbal extracts treatment was given to the rats once daily for eight consecutive 
days. Oral glucose tolerance test was performed and plasma glucose level of the 
rats was determined on day 1 for the acute effect of the herb, and also on day 8 
for the chronic effect of the treatment. 
Rats were firstly randomized into various groups (n > 5): negative control 
group (water, 5ml/kg body weight), positive control group (metformin, 5ml/kg, 
200mg/kg body weight), and herbal extract treatment groups (822mg/kg formula 
1 or 400mg/kg Rhizoma Smilacis Chinensis 诞葜）extract, 5ml/kg body weight). 
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The procedure of oral glucose tolerance test is described as follows: Prior 
to the experiment, the rats were fasted for 2 hours. Then, 300}il of blood samples 
from the rats were collected from tail vein in a 1.5ml microfuge tube containing 
heparin (1250U/ml, 5)Lil/tube). Within 30 minutes after blood sample collection, 
plasma sample was collected by centrifugation of the whole blood sample at 
2000 X g for 5 minutes and the supernatant plasma was transferred to another 
tube and stored on ice. Fifteen minutes after the blood collection, herbal extract, 
water, or metformin was introduced orally to the rats by force-feeding. Blood 
was again collected and plasma was obtained by centrifugation 15 minutes after 
the force-feeding. Glucose solution (400mg/ml, 2g/kg and 5ml/kg body weight) 
was then force-fed to the rats 15 minutes after the blood collection. This time 
point was designated as “0 minute". Blood samples were collected at appropriate 
time points over a period of 90 minutes after the glucose loading. The plasma 
glucose levels were measured by the enzymatic-spectrophotometric glucose 
oxidase/peroxidase assay described in section 4.4.4. Rats were kept unfed 
throughout the whole experimental period. Rats were given the same treatment 
from day 2 to 7 once daily. The oral glucose tolerance test was performed with 
the same procedure on day 8. 
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4.4.3 Basal glycaemia test 
The n5-STZ diabetic rats at the age of week 10 to 12 were used in the 
basal glycaemia test. The diabetic condition was confirmed by the determination 
of fasting hyperglycaemia at 7.0mM or over in the adult rats. The herbal extracts 
treatment was given to the rats once daily for eight consecutive days. Basal 
glycaemia test was performed and plasma glucose level of the rats was 
determined on day 1 for the acute effect of the herb, and also on day 8 for the 
chronic effect of the treatment. 
Rats were firstly randomized into various groups (n > 5): negative control 
group (water, 5ml/kg body weight), positive control group (metformin, 5ml/kg， 
200mg/kg body weight), and herbal extract treatment groups (411mg/kg formula 
1 or 400mg/kg Rhizoma Smilacis Chinensis (菝葜）extract, 5ml/kg body weight). 
The procedure of basal glycaemia test is described as follows: Prior to the 
experiment, the rats were fasted for 2 hours. Then, 300|al of blood samples from 
the rats were collected from tail vein as described in section 4.4.2. Herbal extract, 
water, or metformin was introduced orally to the rats by force-feeding. Blood 
samples were collected at appropriate time points over a period of 360 minutes 
after the treatment. Plasma was collected immediately by centrifugation of the 
blood samples. The rats were kept unfed throughout the experimental period. The 
plasma glucose levels were measured by the enzymatiospectrophotometric 
glucose oxidase/peroxidase assay described in section 4.4.4. Rats were given the 
same treatment from day 2 to 7 once daily. The basal glycaemia test was 
performed with the same procedure on day 8. 
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4.4.4 Plasma glucose level determination 
The plasma glucose levels were measured by an enzymatic-
spectrophotometric glucose oxidase/peroxidase assay kit. The assay was 
performed as follows: 1ml of the assay reagent was aliquoted to 1.5ml microfuge 
tubes and pre-warmed in a 37°C water bath. lOfxl of the plasma sample was 
added to the reagent and then the solution was mixed thoroughly. The mixture 
was incubated at 37°C for 5 minutes. In every set of experiment, a blank and a 
standard were also carried out by adding 10^1 of distilled water and lOfxl of 
standard solution respectively. The absorbance of the plasma sample and the 
standard was measured at 500nm against the blank using a spectrophotometer. 
The glucose concentration in the sample was calculated using the following 
general formula: 
Glucose concentration of the plasma sample 
=(Absorbance of plasma sample / Absorbance of standard) x lOOmg/dl 
4.4.5 Statistical analysis 
Area under the curve (AUC) for glucose level across time was calculated 
for each rat on each day. AUC was used as a summary variable for the 
comparison of efficacy between each herb/formula/drug and water. Multilevel 
modeling was used to examine the effectiveness of each herb/formula/drug in 
reducing AUC (and hence glucose level). The rats' AUC across days were filled 
to multilevel models with adjustments for weight. The public domain software 
MIXREG was used for fitting multilevel models. All statistical tests were two-
sided, with a significant level of p<0.05. 
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4.5 Results 
4.5.1 Oral glucose tolerance test 
a) Formula 1 
Formula 1 was tested for its anti-hyperglycaemic effect by oral glucose 
tolerance test in nO-STZ diabetic rats and the results are shown in Figure 4.2. The 
dosage of formula 1 used in the experiment was 822mg/kg and this was 
determined by twice of human equivalent dose. Metformin at the dosage of 
200mg/kg was used as positive control. Statistical analysis was made by 
comparing area under the curve (AUC) of treatments with that of the water 
control. 
On both days 1 and 8, no significant difference from water group was 
found in formula 1 treatment group. On the other hand, the positive control, 
metformin, significantly lowered the plasma glucose level on both days (p<0.05), 
thereby validating the model. Hence, it is concluded that formula 1 at the dosage 
of 822mg/kg did not have anti-hyperglycaemic effect on the nO-STZ rats. 
After 8 days of treatment, body weights of rats in all groups increased 
gradually and no significant difference was found between treatment groups and 
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Figure 4.2. Oral glucose tolerance test of formula 1 (822mg/kg) treated animals 
on (A) day 1 and (B) day 8 experiment. Formula 1 (822mg/kg), or metformin 
(200mg/kg), or water，was administered orally to the nO-STZ diabetic rats after 2hr 
fasting and 30min before glucose load (2g/kg) (t = 0). Blood was taken at 10, 20, 30, 
45, 60 and 90min after glucose administration. The treatment lasted for 8 consecutive 
days and oral glucose tolerance test was performed on day 1 and day 8 of the 
treatment. Data are expressed as mean 土 SEM (n 二 7 - 8). 
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b) Rhizoma Smilacis Chinensis (蔬葜） 
Rhizoma Smilacis Chinensis was tested for its anti-hyperglycaemic effect 
by oral glucose tolerance test in nO-STZ diabetic rats and the results are shown in 
Figure 4.3. The dosage of Rhizoma Smilacis Chinensis used in the experiment 
was 400mg/kg. Metformin at the dosage of 200mg/kg was used as positive 
control. Statistical analysis was made by comparing area under the curve (AUC) 
of treatments with that of the water control. 
On both days 1 and 8, no significant difference from water group was 
found in Rhizoma Smilacis Chinensis treatment group. On the other hand, the 
positive control, metformin, significantly lowered the plasma glucose level on 
both days (p<0.05)，thereby validating the model Hence, it is concluded that 
Rhizoma Smilacis Chinensis at the dosage of 400mg/kg did not have anti-
hyperglycaemic effect on the nO-STZ rats. 
After 8 days of treatment, body weights of rats in all groups increased 
gradually and no significant difference was found between treatment groups and 
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Figure 4.3. Oral glucose tolerance test of Rhizoma Smilacis Chinensis 
(400ing/kg) treated animals on (A) day 1 and (B) day 8 experiment. Rhizoma 
Smilacis Chinensis (400mg/kg), or metformin (200mg/kg), or water, was 
administered orally to the nO-STZ diabetic rats after 2hr fasting and 30min before 
glucose load (2g/kg) (t = 0). Blood was taken at 15, 30, 45, 60 and 90min after 
glucose administration. The treatment lasted for 8 consecutive days and oral glucose 
tolerance test was performed on day 1 and day 8 of the treatment. Data are expressed 
as mean 土 SEM (n 二 18 - 22). 
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4.5.2 Basal glycaemia test 
a) Formula 1 
Formula 1 was tested for its effect on fasting glucose level by basal 
glycaemia test in n5-STZ diabetic rats and the results are shown in Figure 4.4. 
The dosage of formula 1 used in the experiment was 411mg/kg and it was 
determined by the human equivalent dose. Metformin (200mg/kg) was used 
as positive control. Statistical analysis was made by comparing area under the 
curve (AUC) of treatments with that of the water control. 
Although no significant difference from water group was found in 
formula 1 treatment group on both days 1 and 8，the AUC value was about 
8.6% and 8.1% lower than that of water control group on day 1 and day 8, 
respectively. The positive control, metformin, significantly lowered the 
plasma glucose level on both days (p<0.05), thereby validating the model. 
Hence, it is concluded that formula 1 at the dosage of 411mg/kg did not 
significantly lowered the fasting glucose on the n5-STZ rats. Experiment on 
nO-STZ rats with 822mg/kg formula 1 treatment was also performed and 
similar result was obtained (Appendix II). 
After 8 days of treatment, body weights of rats in all groups increased 
gradually and no significant difference was found between treatment groups 
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Figure 4.4. Basal glycaemia test of formula 1 (411mg/kg) treated animals on (A) 
day 1 and (B) day 8 experiment. Formula 1 (411mg/kg), or metformin (200mg/kg), 
or water, was administered orally to the n5-STZ diabetic rats after 2hr fasting (t = 0). 
Blood was taken at 45, 90, 135, 180, 240 and 360min after treatment. The treatment 
lasted for 8 consecutive days and basal glycaemia test was performed on day 1 and 
day 8 of the treatment. Data are expressed as mean 土 SEM (n = 5 - 7). 
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b) Rhizoma Smilacis Chinensis (蔬葜） 
Rhizoma Smilacis Chinensis was tested for its effect on fasting 
glucose level by basal glycaemia test in n5-STZ diabetic rats and the results 
are shown in Figure 4.5. The dosage of Rhizoma Smilacis Chinensis used in 
the experiment was 400mg/kg. Metformin at the dosage of 200mg/kg was 
used as positive control. Statistical analysis was made by comparing area 
under the curve (AUC) of treatments with that of the water control. 
On both days 1 and 8，no significant difference from water group was 
found in Rhizoma Smilacis Chinensis treatment group. On the other hand, the 
positive control, metformin, significantly lowered the plasma glucose level on 
both days (p<0.05), thereby validating the model Hence, it is concluded that 
Rhizoma Smilacis Chinensis at the dosage of 400mg/kg did not have glucose-
lowering effect on fasting glucose on the n5-STZ rats. 
After 8 days of treatment, body weights of rats in all groups increased 
gradually and no significant difference was found between treatment groups 
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Figure 4.5. Basal glycaemia test of Rhizoma Smilacis Chinensis (400mg/kg) 
treated animals on (A) day 1 and (B) day 8 experiment. Rhizoma Smilacis 
Chinensis (400mg/kg), or metformin (200mg/kg), or water, was administered orally 
to the n5-STZ diabetic rats after 2hr fasting (t = 0). Blood was taken at 45, 90, 135, 
180, 240 and 360min after treatment. The treatment lasted for 8 consecutive days 
and basal glycaemia test was performed on day 1 and day 8 of the treatment. Data are 
expressed as mean 土 SEM (n= 12 - 13). 
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4.6 Discussion 
The STZ diabetic rat model has long been used for the study of diabetes (Portha 
et al., 1974). In this project, the nO-STZ rats were used in the oral glucose tolerance 
test while the n5-STZ rats were used in the basal glycaemia test. The severe 
hyperglycaemia condition created in the n5-STZ rats provides a more sensitive 
model for the basal glycaemia test. Basal glycaemia test was also conducted in nO-
STZ rats. However, the hypoglycaemic effect observed in metformin treatment was 
slight. For the herbs that were expected to be not as powerful as metformin, the nO_ 
STZ model is not sensitive enough for the detection of the hypoglycaemic effect of 
the herbs (Appendix 11). Metformin produces hypoglycaemia in diabetic animals by 
an extrapancreatic mechanism and do not have significant activity in normal animals 
(El-Fiky et al., 1996). In the present study, results showed that metformin could 
significantly decrease the plasma glucose level in diabetic animals in all sets of 
experiments (Figure 4.2 to Figure 4.5). Therefore，the diabetic condition of the 
animal model was confirmed. 
Formula 1 and Rhizoma Smilacis Chinensis were tested for their anti-diabetic 
effects in the STZ diabetic rat model. However, no significant hypoglycaemic and 
anti-hyperglycaemic effects were observed. The dosage of formula 1 used in the 
animal study is equivalent to the human dose or twice of the human dose. However, 
the dosage for in vivo study of Rhizoma Smilacis Chinensis (400mg/kg) in the in 
vivo study was much higher than that of the human equivalent dose (38.8mg/kg) 
(State Pharmacopoeia Commission, 2000; Freireich et al., 1966). Preliminary test on 
the human equivalent dose of Rhizoma Smilacis Chinensis did not show anti-diabetic 
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effect in the animal model (data not shown). Therefore, a higher dosage was used for 
the study of the in vivo anti-diabetic effect of Rhizoma Smilacis Chinensis extract. 
Although formula 1 and Rhizoma Smilacis Chinensis showed promising effect 
in the in vitro screening systems, they had no significant effect in the in vivo systems. 
Such disagreement in the two systems may be due to the following: (1) The active 
compounds in the herbal extracts might have been broken down through digestion or 
these compounds were not absorbed into the bloodstream. (2) The dosage used in the 
in vivo assays did not match the effective dosage observed in the in vitro screening 
systems. It is always a difficult task to correlate the dosage used in in vitro systems 
with that in in vivo systems for these crude herbal extracts because these extracts 
contain a number of compounds, which may have different absorption efficiency. (3) 
The animal model has some limitations. Some consider this model representative of 
type 2 diabetes while some have reservations. Neonatal streptozotocin-induced 
diabetic rat model is the model of diabetes associated with substantial reduction in 
pancreatic P - c e l l mass and this feature is also present in diabetic patients (Stefan et 
al., 1982). However, insulin secretion was insensitive to glucose challenge (Leahy et 
al., 1984) and sulphonylureas (Weir et al” 1981) in the STZ-induced diabetic rats, 
which does not occur in human. Therefore, the anti-diabetic effects of the herbs 
might not be detected if these herbs mimic the action of sulphonylureas. Moreover, 
insulin resistance is only present in the n5-STZ rats, but not in nO-STZ rats (Blondel 
et aL, 1989; Kergoat and Portha, 1985). 
In the future, other diabetic animal models can be used, such as the genetically 
manipulated diabetic rat models, e.g. db/db mice. Other chemically manipulated 
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diabetic rat models can be used, such as the rat model induced by the injection of 
streptozotocin and nicotinamide, the pancreatic p-cell protective agent, which 
showed sensitivity to sulphonylureas (Masiello et al., 1998). However, it must be 
noted that none of the current diabetic animal models are equivalent to the human 
condition (Bell and Hye, 1983). 
From section 2.5.3, it was found that the herbal extracts contained glucose, 
fructose and sucrose. In this regard, one may be concerned that the presence of the 
sugars may affect the plasma glucose level However, if the amounts of these sugars 
were low, the plasma glucose level would not be affected. The amount of sugars in 
formula 1 and Rhizoma Smilacis Chinensis extract was calculated and is shown in 
Table 4.1. Glucose released from the herbal extracts should come from the free 
glucose and sucrose. Sucrose releases glucose and fructose at 1:1 ratio under 
digestion. Concerning oral glucose tolerance test, 2000mg/kg of glucose was 
administered to the rats. The amount of glucose released from formula 1 (822mg/kg) 
and Rhizoma Smilacis Chinensis (400mg/kg) was responsible for 2.33% and 1.06% 
of the glucose load, respectively. Concerning basal glycaemia test, the amount of 
glucose released from formula 1 (411mg/kg) and Rhizoma Smilacis Chinensis 
(400mg/kg) was at a dosage of 23.33mg/kg and 21.28mg/kg, respectively. Therefore， 
it is believed that the glucose released from the herbal extracts would not interfere 
with the in vivo test results. 
In conclusion, formula 1 and Rhizoma Smilacis Chinensis did not show anti-
hyperglycaemic and hypoglycaemic effects in vivo. In the next chapter, the effects of 
formula 1 and formula 2 on erythrocyte glucose uptake and fasting plasma glucose 
levels in diabetic patients receiving the formulae treatment are discussed. 
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Amount of glucose received by the rats 
Dosage (mg/kg body weight) 
n。， Glucose released D-Glucose Total from sucrose 
822mg/kg 16.93 29.72 46.65 Formula 1 
411mg/kg 8.47 14.86 23.33 
Rhizoma Smilacis Chinensis 400mg/kg 21.28 0 21.28 
Table 4.1. The amount of glucose received by the rats in the in vivo study. The 
amount was calculated from the HPLC analysis of the sugar content in the herbal 
extracts in section 2.5.3 and the dosage used in the animal study. 
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Chapter 5: The effects of the TCM treatment on glucose 
homeostasis in diabetic foot ulcer patients 
5.1 Introduction 
In type 2 diabetes, hyperglycaemia is the main feature and normal glucose 
homeostasis cannot be maintained due to insulin resistance and impaired insulin 
secretion. It was found that reduction in both insulin-stimulated glucose uptake and 
basal glucose uptake play important role in the development of diabetes (Forbes et 
al., 1998). 
Glucose transporter 1 (Glutl) is present in nearly all tissues and plays pivotal 
roles in basal glucose uptake (Mueckler, 1990). In diabetes, the basal glucose uptake 
in the patients is diminished and reduction of the intrinsic activity of Glutl accounts 
for such defect (Comi and Hamilton, 1994). Glutl is most abundant in the 
erythrocytes and it is the only type of glucose transporter present on the erythrocyte 
membrane. Erythrocytes transport 40% of blood glucose and it is the most important 
tissues after the brain in terms of glucose consumption (Jacquez, 1984). Glucose 
transport and metabolism were reported to be reduced in type 2 diabetic patients 
(Donatelli et al., 1991), which the reduced Glutl activity on the erythrocyte 
membrane is due to the Glutl structural change (Hu et al, 2000). 
Owing to the lack of nucleus in erythrocytes, the high content of Glutl in 
erythrocyte membrane is steady and there is no new protein biosynthesis. Therefore, 
the erythrocyte is a good model to study the activity of Glutl protein. Using 
erythrocyte as a model of basal glucose transport, Yoa et al. (1993) demonstrated 
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that a defect in glucose uptake exists in erythrocytes from diabetic patients and this 
defect is reversed by metformin which is known to promote basal glucose transport 
in diabetes (Kumar and Dey, 2002). 
In this part of the project, the effect of formula 1 and formula 2 treatment on 
basal glucose transport was studied in diabetic patients. Patients were recruited and 
subjected to TCM or placebo treatment on a double-blind basis. Blood samples were 
taken from the patients and zero-trans influx glucose uptake experiment in the 
erythrocytes was performed to determine Glutl activity. Comparison was made 
between the erythrocyte glucose uptake before and after treatment. The effects of the 
treatment on the fasting plasma glucose concentration of the patients were also 
studied. 
5.2 Objective 
The objective of this part of the project is to study the effects of formula 1 and 
formula 2 treatment on systemic and cellular glucose homeostasis by measuring 
fasting plasma glucose level and erythrocyte glucose uptake in diabetic patients. 
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5.3 Materials 
5.3.1 Study subjects 
Diabetic foot ulcer patients were recruited to the project investigating the 
effect of the TCM formulae, formula 1 and formula 2，on the healing of diabetic 
foot ulcer. The patients were recruited from Prince Wales Hospital, Hong Kong 
and these patients were diagnosed as diabetes complicated with diabetic foot 
ulcer (Leung et al., unpublished data). As most of the patients had a long duration 
of diabetes, they received anti-diabetic medication during the formulae study. 
Patients admitted to the project were under formulae treatment on a 
random double-blind basis, indicating that approximately half of the patients 
received TCM formulae treatment and half of them received placebo. 
Placebo were made with cellulose and coloured to the same as the herbal extract, 
identical in appearance, smell, taste and weight with the formulae. Apart from 
double-blind basis, some patients were recruited as service cases, which means 
that they are not part of the double-blind basis clinical trial and they were given 
TCM formulae for ulcer treatment. In total, eight patients were recruited into the 
randomized clinical study, which were designated as "study case". At the end of 
the study, the treatment received by each patient was revealed and it was found 
that four cases were in TCM formulae treatment group and four cases in the 
placebo group. Moreover, three patients were recruited as ‘‘service cases" and 
they received TCM formulae treatment group. Therefore, seven patients received 
TCM treatment and four patients received placebo treatment. Blood was taken 
from the patients before the start of the therapy and after the end of the therapy, 
which the patients stopped receiving treatment. 
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5.3.2 Blood sample 
Blood is preserved at 4°C in coagulation tubes containing 3.2% (w/v) 
sodium citrate. The glucose uptake assays were performed within 2 days after the 
blood was taken. 
5.3.3 Chemicals and reagents for erythrocyte glucose uptake 
assay 
(a) 3-O-Methyl-D-gluco-pyranose (3-OMG) 
3-OMG was purchased from Sigma (St. Louis, MO, USA). The powder 
was dissolved in PBS as a stock solution of lOmM and stored at 4°C until use. 
(b) ^^C-labeled 3-OMG 
The stock solution (56.4mCi/mmol) was purchased from PerkinElmer 
Life Science, Inc. (Boston, MA, USA) and kept at -20°C. 
(c) Stop solution 
The stop solution contained lOOjiM mercuric chloride and 50}iM 
phloretin in ice-cold PBS, prepared immediately before use. 
(i) Phloretin 
Phloretin (aglycone of phlorizin) was purchased from Sigma (St. 
Louis, MO, USA). It was freshly prepared by dissolving 13.75mg of 
phloretin powder in 0.5ml 95% ethanoL 
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(ii) Mercuric chloride 
Mercuric chloride (HgClz) was purchased from Sigma (St. Louis, MO, 
USA). It was freshly prepared by dissolving 27.15mg mercuric chloride 
powder in 1ml of PBS. 
(d) Cell solublizing agent 
Cell solublizing agent was prepared by mixing isopropyl alcohol (Sigma, 
St. Louis，MO，USA) and soluene-350 (Packard Bioscience, Meriden，CT，USA) 
in the ratio of 1:2. 
(e) Hydrogen peroxide 30% (v/v) (H2O2) 
H2O2 was purchased from BDH Laboratory (Dorset, United Kingdom) and 
stored at 4°C. 
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5.4 Methods 
5.4.1 Preparation of blood sample 
One to two millilitre of blood was washed twice by 5 volume of PBS and 
centrifuged at 805 x g for 4 minutes at 4°C. Supernatant was discarded, and 
erythrocytes were then incubated with PBS on wet ice for 15 minutes to achieve 
zero-trans (no intracellular glucose) condition, followed by centrifugation and the 
removal of supernatant. Erythrocytes were then re-suspended in PBS to the 
original blood-sample volume. Fifty microlitres aliquots were taken for 
immediate assay, and lO^il were used for cell count. 
5.4.2 Zero-trans influx of 3-OMG uptake in erythrocytes 
The Lowe and Walmsley techniques were modified as previously 
described (Klepper et al., 1999; Lowe and Walmsley，1986). Briefly，SOjil of 
blood aliquot was incubated with 100\i\ of hot/cold 3-OMG mixture (H/C 
solution) containing IpiCi/ml of ^^C-3-OMG and 0.6mM of cold 3-OMG. The 
uptake reactions with i^C-labeled 3-OMG were allowed to proceed at 4°C and 
the reaction was stopped at different time points over a period of 30 seconds. 
Equilibrium uptake of ^"^C-labeled 3-OMG was measured after 25 minutes 
incubation. 3-OMG influx was terminated by addition of 1ml ice-cold stop 
solution followed by the washing steps carried out at room temperature. After 
centrifugation for 20 seconds, the erythrocyte pellet was washed twice with 1ml 
of ice-cold stop solution. Cell pellet in each tube was then digested with 250fil of 
solublizing agent. At room temperature, the samples were bleached with 250jil 
of 30% v/v hydrogen peroxide. The mixture was swirled until all foaming 
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subsided. Four milliliters of OptiPhase HiSafe 2 scintillation fluid (PerkinElmer 
Life sciences, Inc., Boston, MA, USA) was added to each sample, and 
radioactivity in aliquots was determined by a Packard Tri-Carb® 2900TR liquid 
scintillation counter. 
5.4.3 Statistical analysis 
For the statistical analysis, data were entered into and analyzed by using 
SPSS for Windows (version 11.5, SPSS Inc, Chicago, IL, USA). Mann-Whitney 
tests were used for the comparisons in all experiments between the data before 
and after treatment in both TCM treatment and placebo groups. Statistical tests 
were two-sided, with a significant level of 0.05. 
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5.5 Results 
In the present study, eleven patients were tested for the effects of the 
formulae or placebo on fasting plasma glucose concentration and erythrocytes 
glucose uptake. The profiles of the patients are shown in Table 5.1. Seven of them 
received TCM formulae treatment and four of them received placebo treatment. 
The fasting plasma glucose concentration and the erythrocytes glucose uptake 
were measured before and after the course of treatment. Figure 5.1 shows the fasting 
plasma glucose concentration of the patients in both treatment and placebo groups. 
When considering the fasting plasma glucose concentration of individual patients, 
although drastic changes were observed in some patients, the average glucose 
concentration in both groups did not change significantly (Figure 5.1 A, B and C). 
Mild decrease of fasting plasma glucose level was observed in TCM treatment group, 
but such decrease did not reach statistical significance (Figure 5.ID). 
The erythrocyte glucose uptake of the patients is shown in Figure 5.2. 
Similarly, both TCM formulae treatment and placebo treatment did not significantly 
change the erythrocyte glucose uptake activity. The differences observed in all the 
treatment group did not reach statistical significance. 
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Treatment 
Sample size (N) Age Gender duration 
(Weeks) 
Study case 4 78.5 土 4.1 8.0 土 3.3 r = Z TCM group 
Service case 3 60.7 土 10.9 ^ ^ ^ 8.3 土 4.5 
Placebo 4 69.7 ±1 .2 3.5 ±0.6 
Table 5.1. The sample size, age and gender distribution of the patients in TCM 
formulae treatment group and placebo treatment group. 
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Figure 5.1. Fasting plasma glucose concentrations of patients before and after 
(A) TCM formulae treatment in study case, (B) TCM formulae treatment in 
service case and (C) placebo treatment, and (D) the average values in each 
treatment group. The fasting plasma glucose concentration was measured after 
overnight fasting. Data are expressed as mean + SEM (n = 4 for TCM treatment 
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Figure 5.2. The erythrocyte 3-OMG uptake of the patients before and after (A) 
TCM formulae treatment in study case, (B) TCM formulae treatment in service 
case and (C) placebo treatment. Erythrocytes were incubated with ^"^C-S-OMG at 
4°C. Reaction was stopped at different time points over a period of 30 sec. 3-OMG 
influx was terminated by the addition of ice-cold stop solution. The amount of 
radioactive glucose influx was normalized by cell count. Data are expressed as mean 
土 SEM (n 二 4 for placebo group; n 二 7 for TCM treatment group). 
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5.6 Discussion 
In this study, the formulae treatment did not improve the fasting plasma 
glucose value and the erythrocyte glucose uptake in diabetic patients. With regards to 
the rationale of this project, the anti-diabetic effects of the formulae were studied 
because the patients were prescribed with these formulae, as well as conventional 
anti-diabetic medications, and it may cause hypoglycaemia in patients if these 
formulae also possess strong hypoglycaemic effect. In the present study, it is 
demonstrated that these formulae do not have significant hypoglycaemic effect on 
the patients. 
The erythrocyte glucose uptake was not improved by the formulae treatment in 
patients. This may also be due to the parallel formulae treatment and anti-diabetic 
medications, masking the effect of the formulae treatment. From previous report, 
metformin treatment can restore the defective erythrocyte glucose uptake in diabetic 
patients (Yoa et al, 1993; Rapin et al.’ 1991). When compared with the erythrocyte 
glucose uptake in normal subjects (Wong et aL, unpublished data)，the uptake in 
diabetic patients in this study was not significantly changed when compared to that 
of normal. However, other studies have shown that the erythrocyte glucose uptake in 
the diabetic patients is only about 60% of the normal (Hu et al, 2000; Comi and 
Hamilton, 1994). This indicates that the anti-diabetic medication may have improved 
the erythrocyte glucose uptake in these patients through glycaemia control. 
Moreover, since the turnover rate of erythrocytes is about 110 days (Strocchi et al, 
1992) and the patients seldom received the formulae treatment for such long time, 
the lack of effect of the formulae treatment on erythrocyte glucose uptake may be 
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due to the insufficient time for the actions of the formulae to be reflected on 
erythrocyte Glutl activity. 
The studies are still ongoing at this moment. Moreover，owing to the very small 
sample size, the results were preliminary and further study is needed to confirm the 
effects of the formulae treatment on systemic glucose homeostasis in human. More 
information about the glycaemic control of the patients will be measured in the future, 
e.g. HbAlc, plasma insulin and TNF-a level. At present, the formulae treatment did 
not show significant effects on regulating plasma glucose level or erythrocyte 
glucose transport in diabetic patients. 
- t 
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Chapter 6: General discussion and conclusion 
6.1 Overview of the project and analysis of research findings 
Type 2 diabetes mellitus is a major health burden in the world. The prevalence 
of diabetes surges dramatically in recent years (Lieberman, 2003). However, current 
therapies have limited efficacy, limited tolerability and significant side effects 
(Moller, 2001). Therefore，the search for new anti-diabetic agents is much needed. 
Medicinal plants have always been one of the main research interests and new anti-
diabetic agents may be discovered from these traditionally used herbs. 
托毒生肌顆粒劑（Formula 1) and耆味地黃顆粒劑（Formula 2) are two 
traditional Chinese medicine formulae designed for diabetic foot ulcer treatment. In 
this project, anti-diabetic activities of these traditional Chinese medicine formulae 
were systematically studied. Because it is a possible mechanism contributing to the 
therapeutic effects of formulae on diabetic foot ulcer. It was hypothesized that these 
formulae and their component herbs possess anti-diabetic activities. The main focus 
of this project is on formula 1 while formula 2 and its component herbs have been 
tested by the other member of this project. 
Before the herbs were used in the experiments，morphological studies were 
employed to authenticate these herbs and their authenticities were further supported 
by their thin layer chromatographic profiles. The anti-diabetic activities of formula 1 
and its component herbs were studied using both in vitro and in vivo models (Figure 
6.1). The in vitro systems were employed to firstly screen the effects of the herbal 
extracts on modulating tissue glucose homeostasis. The herbs showing potent effects 
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in the in vitro screening systems were further studied for their in vivo anti-diabetic 
effects by using the neonatal-STZ diabetic rat model. Furthermore，the effects of the 
formulae treatment on the fasting plasma glucose level and the erythrocyte glucose 
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Figure 6.1. The systematic approach used in this project for the investigation of 
the anti-diabetic activities of formula 1 and its component herbs. Four in vitro 
models were employed in the screening process: 3T3-L1 mouse adipocytes and Hs68 
human skin fibroblasts were used as the models to study the effect of herbal extracts 
on peripheral tissues glucose transport. H4nE rat hepatoma cells were used as the 
model to study the effects of the herbal extracts on hepatic gluconeogenesis. BBMV 
was used as the model to study the effects of the herbal extracts on intestinal glucose 
absorption. The anti-diabetic effect of the herbs on systemic blood glucose was 
studied by using the STZ-induced diabetic rat model. 
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Significant findings of this project include: 
(1) The extracts of formula 1 and its component herbs were found active 
in modulating tissue glucose homeostasis in the in vitro studies. 
(2) Formula 1 and Rhizoma Smilacis Chinensis did not exert anti-
hyperglycaemic or hypoglycaemic effects in the in vivo animal 
studies. 
(3) Formula 1 and formula 2 treatment did not significantly improve 
fasting plasma glucose level or erythrocyte glucose uptake in the 
diabetic patients in the clinical studies. 
The formulae showed prominent effects on treating diabetic foot ulcer，but 
neither formula 1 nor its component herbs significantly lowered blood glucose level 
in patients or in animal studies. Nevertheless, these herbal extracts did modulate 
tissue glucose homeostasis in vitro. These observations indicate that the therapeutic 
effects of formula 1 on foot ulcer are not primarily mediated by normalizing systemic 
glycaemic control in vivo. In TCM theory, the treatment of diabetes emphasizes the 
relief of the symptoms and restoration of the inner-balance of body rather than the 
lowering of blood glucose (Zhou, 2001). Therefore, formula 1 may not exert its 
effect by directly lowering the blood glucose level. Rather, the therapeutic effect on 
diabetic foot ulcer of formula 1 may be mediated by the improvement of the 
peripheral tissue glucose homeostasis as shown in the in vitro studies. 
Diabetic foot ulcer is a complication of diabetes mellitus. Common treatment 
mechanisms include anti-inflammation, tissue generation and angiogenesis (Mason et 
al., 1999). Formula 1 was designed to treat diabetic foot ulcer through strengthening 
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of the muscle, swelling control, removal of the debridement and promotion of wound 
granulation. The effects of the formulae on diabetic foot ulcer are studied by another 
project team member. According to previous studies, some of the component herbs 
are reported to possess tissue generative effect (Radix Astragali), anti-inflammatory 
effect (Radix Rehmanniae) and enhancing effect on circulation (Rhizoma Smilacis 
Chinensis and Radix Polygoni Multiflori Preparata) (Lu et al., 1999; State 
Administration of Traditional Chinese Medicine, 1999). These herbal effects may be 
the mechanisms underlying the therapeutic effects of formula 1 on foot ulcer. Since 
formula 1 was not designed for treating diabetes, it is not surprising that this formula 
does not improve in vivo glycaemic control. 
Inconsistent results were observed in the in vitro and in vivo investigation of the 
herbs. Formula 1 and Rhizoma Smilacis Chinensis regulated cellular glucose 
homeostasis in the in vitro systems but they did not lower glucose level in the in vivo 
studies. This inconsistency may be due to the amount of the active compounds 
absorbed into the systemic circulation in the in vivo study did not reach the effective 
dosage observed in the in vitro screening systems. Moreover, the active compounds 
in the herbal extract might have been degraded in the digestive tract. The formulae 
did not exert significant effects on glucose homeostasis in the clinical studies either, 
possibly due to the parallel anti-diabetic medication received by the diabetic patients. 
From the work of my fellow, Mr. Lau Chun Hong (M.Phil, candidate, Institue 
of Chinese Medicine, The Chinese University of Hong Kong), who studied the anti-
diabetic activities of formula 2, results also showed that formula 2 can modulate in 
vitro glucose homeostasis but it did not improve the glycaemic control in the in vivo 
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studies. Although both formula 1 and formula 2 did not show hypoglycaemic effects 
in the in vivo studies, the results may indicate that these formulae give benefits to the 
clinical studies. In the clinical studies, the patients received both formulae and 
conventional anti-diabetic medication treatment. If the formulae possessed glucose 
lowering effects, it would cause undesirable hypoglycaemia in the patients. From our 
results, we can tell that it is safe for the patients to receive both formulae and 
medication treatment without worrying about the side effect of hypoglycaemia. 
6.2 Limitations of the study 
Herbal medicines were used as the only way of treatment for diabetes in 
ancient China. Although scientific background of the use of these herbs is 
insufficient, it is believed that some of these herbal medicines possess anti-diabetic 
activity. In the present study, one TCM formula and its six component herbs were 
studied for their anti-diabetic activities. However, quality control and standardization 
of these herbal medicines are always a concern for TCM research. The chemical 
composition and the efficacy of these herbal medicines are affected by a lot of 
factors, from agricultural conditions to storage. To limit this variability, a single 
batch of herbal material was used for extract preparation. However, the positive 
effect shown in the present study is not necessarily reproducible in another batch of 
the same species of herbs. This is the intrinsic limitation of herbal medicine research 
and can be solved by the standardization of TCM through measures like good 
agricultural practice (GAP) (Yang et al, 2003). 
Moreover, in traditional Chinese medicine theory, formulae containing more 
than one herb are often used for treatment. The effect of each component herbs may 
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be very mild in the formula (Meng et aL, 2000). Interactions between component 
herbs, like synergistic effect and neutralization of toxicity, may be present (Zhang 
and Wumanjiang, 2003). However，the study of the action of each component herbs 
in the formula is the most simple and effective way to isolate the active components 
in the formula. 
Traditional Chinese herbs are usually boiled with water as decoction for 
medicinal use. Compliance to this traditional use of Chinese herbs, water extracts of 
the herbs were used for investigation in this project. However, water extraction 
inevitably leads to the loss of non-polar compounds in the herbs，e.g. alkaloids and 
flavonoids. Although the anti-diabetic activity of these non-polar compounds in the 
herbs of this project is not known, active non-polar compounds with anti-diabetic 
activity have been isolated from other herbs (Miura et aL, 2001; Shi and Zhang, 
2000). Therefore, active non-polar compounds may also be present in the component 
herbs of formula 1. However, their anti-diabetic activities were not studied in the 
present investigation. 
6.3 Future directions 
There are two main future directions to investigate the traditional Chinese 
medicines for their potential therapeutic effects on diabetes: investigation of the anti-
diabetic activity of other traditional Chinese medicines and isolation of active 
compounds from the herbs in the present study. 
Although systemic glucose-lowering effect was not observed in formula 1 and 
its component herbs, it is still possible that other traditional Chinese medicinal herbs 
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possess anti-diabetic activity because TCM has been used for diabetic treatment 
since ancient time. Therefore, other herbs with potential anti-diabetic activities can 
be investigated in the future. Ethnopharmacological approach (the study of 
differences in response to drugs based on varied ethnicity) should be used instead of 
random selection of the herbs. Ethnopharmacological approach allows recognition of 
potential herbs by their traditional uses in diabetes treatment and provides a more 
effective way with greater success rate to identify the anti-diabetic herbs (Heinrich 
and Gibbons, 2001). For example, Radix Trichosanthis (天花粉)，Rhizoma Coptidis 
(黃連)，Raidix Ophiopogonis (麥冬）and Rhizoma Anemarrhenae (知母）are the 
common ingredients of formulae used in traditional diabetes treatment (Wu and Ren, 
2002) and their anti-diabetic activity can be confirmed using the screening system 
presented in the present study. 
Another approach for further investigation of the traditional Chinese medicines 
for their potential therapeutic effect on diabetes is the isolation of active compounds 
from the herbs in the present study. Although significant glucose-lowering effects 
were not found in formula 1 and Rhizoma Smilacis Chinensis in the in vivo study, 
they showed promising effects in the in vitro screening systems. The active 
compound(s) responsible for their effects in vitro is unknown. Nevertheless, these 
active compounds could be effective in improving glycaemic control in vivo, 
although further investigation is required. Bioassay-guided fractionation can be used 
to isolate the active compounds in the herbs followed by a simple bioassay, e.g. 
BBMV, to identify the active fraction of the herbal extracts. 
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Apart from the above two main future directions, other in vitro studies can also 
be performed in the future. As mentioned in section 1.5.2, pancreas is one of the 
major therapeutic targets for anti-diabetic medications. Therefore, stimulation of 
insulin release by the herbal extracts can also be studied in the future and such in 
vitro investigation can be carried out by using insulin-secreting cell line, such as rat 
insulinoma RIN m5F cells (Murakami et aL, 1992). 
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6.4 Conclusion 
In the present study, the traditional Chinese medicine formula used for treating 
diabetic foot ulcer, formula 1 (托毒生肌顆粒齊!j)，was studied with the hypothesis 
that this formula and its component herbs possess anti-diabetic activities. 
A systematic approach has been established to investigate the anti-diabetic 
activities of the traditional Chinese medicinal herbs. Our research findings indicated 
that formula 1 and its component herbs modulate glucose homeostasis at the tissue 
levels without improving systemic glycaemic control. 
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Appendix 1. The determination of the sugar contents in the herbal 
water extracts by high performance liquid chromatography 
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C) The HPLC chromatogram of Radix Astragali (黃耆)• 
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D) The HPLC chromatogram of Radix Rehmanniae (生地). 
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E) The HPLC chromatogram of Rhizoma Smilax China (蔬契). 
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F) The HPLC chromatogram of Rhizoma Atractylodis Macrocephalae (白 
Jft). 
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G) The HPLC chromatogram of Radix Polygoni Multiflori (制首烏)• 
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H) The HPLC chromatogram of Radix Stephaniae Tetrandrae (漢防己)• 
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宗 — F o r m u l a 1 (822m g/kg) 
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Basal glycaemia test of formula 1 (822mg/kg) treated animals on (A) day 1 and 
(B) day 8 experiment. Formula 1 (822mg/kg), or metformin (200mg/kg), or water, 
was administered orally to the nO-STZ diabetic rats after 2hr fasting (t — 0). The 
treatment lasted for 8 consecutive days and basal glycaemia test was performed on 
day 1 and day 8 of the treatment. Data are expressed as mean 土 SEM (n = 6 - 7). 
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